KR20020067490A - Preparation of [4S-(4α,7α,10aβ)]-4-Amino-Octahydro-5-Oxo-7H-Pyrido[2,1-b][1,3]Thiazepine-7-Carboxylic Acid, Methyl Ester and Salts Thereof via Novel Disulfides - Google Patents
Preparation of [4S-(4α,7α,10aβ)]-4-Amino-Octahydro-5-Oxo-7H-Pyrido[2,1-b][1,3]Thiazepine-7-Carboxylic Acid, Methyl Ester and Salts Thereof via Novel Disulfides Download PDFInfo
- Publication number
- KR20020067490A KR20020067490A KR1020027001165A KR20027001165A KR20020067490A KR 20020067490 A KR20020067490 A KR 20020067490A KR 1020027001165 A KR1020027001165 A KR 1020027001165A KR 20027001165 A KR20027001165 A KR 20027001165A KR 20020067490 A KR20020067490 A KR 20020067490A
- Authority
- KR
- South Korea
- Prior art keywords
- formula
- disulfide
- produce
- acid
- reacting
- Prior art date
Links
- 150000004702 methyl esters Chemical class 0.000 title claims abstract description 33
- 150000003839 salts Chemical class 0.000 title claims abstract description 25
- 238000002360 preparation method Methods 0.000 title claims abstract description 8
- 150000002019 disulfides Chemical class 0.000 title claims 4
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims abstract description 76
- 150000003951 lactams Chemical class 0.000 claims abstract description 41
- GINSNWSGZOGOGB-ZETCQYMHSA-N methyl (2s)-2-amino-6,6-dimethoxyhexanoate Chemical compound COC(OC)CCC[C@H](N)C(=O)OC GINSNWSGZOGOGB-ZETCQYMHSA-N 0.000 claims abstract description 31
- -1 2-mercapto-1-oxo-3-phenylpropyl Chemical group 0.000 claims abstract description 24
- 239000000178 monomer Substances 0.000 claims abstract description 24
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract description 10
- 238000007363 ring formation reaction Methods 0.000 claims abstract description 7
- 239000003377 acid catalyst Substances 0.000 claims abstract description 5
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 123
- 150000001875 compounds Chemical class 0.000 claims description 43
- 238000000034 method Methods 0.000 claims description 39
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 36
- 239000003153 chemical reaction reagent Substances 0.000 claims description 31
- ZTVZLYBCZNMWCF-WDSKDSINSA-N L,L-homocystine zwitterion Chemical compound OC(=O)[C@@H](N)CCSSCC[C@H](N)C(O)=O ZTVZLYBCZNMWCF-WDSKDSINSA-N 0.000 claims description 30
- 239000002253 acid Substances 0.000 claims description 29
- 238000005859 coupling reaction Methods 0.000 claims description 25
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 24
- 230000008878 coupling Effects 0.000 claims description 23
- 238000010168 coupling process Methods 0.000 claims description 23
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 claims description 23
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 19
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 claims description 18
- 125000006239 protecting group Chemical group 0.000 claims description 18
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical group C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 claims description 15
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 14
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 12
- STSCVKRWJPWALQ-UHFFFAOYSA-N TRIFLUOROACETIC ACID ETHYL ESTER Chemical compound CCOC(=O)C(F)(F)F STSCVKRWJPWALQ-UHFFFAOYSA-N 0.000 claims description 11
- 239000000843 powder Substances 0.000 claims description 10
- TUQOTMZNTHZOKS-UHFFFAOYSA-N tributylphosphine Chemical compound CCCCP(CCCC)CCCC TUQOTMZNTHZOKS-UHFFFAOYSA-N 0.000 claims description 10
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 7
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 7
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 6
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 claims description 6
- HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 claims description 6
- 239000003638 chemical reducing agent Substances 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 235000019253 formic acid Nutrition 0.000 claims description 6
- XVRMRUGVKYSRBZ-LURJTMIESA-N (2s)-2-amino-6,6-dimethoxyhexanoic acid Chemical compound COC(OC)CCC[C@H](N)C(O)=O XVRMRUGVKYSRBZ-LURJTMIESA-N 0.000 claims description 5
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 claims description 5
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 5
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 claims description 5
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 5
- LLSDKQJKOVVTOJ-UHFFFAOYSA-L calcium chloride dihydrate Chemical compound O.O.[Cl-].[Cl-].[Ca+2] LLSDKQJKOVVTOJ-UHFFFAOYSA-L 0.000 claims description 5
- 229940052299 calcium chloride dihydrate Drugs 0.000 claims description 5
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 5
- 229910052751 metal Inorganic materials 0.000 claims description 5
- 239000002184 metal Substances 0.000 claims description 5
- 125000004492 methyl ester group Chemical group 0.000 claims description 5
- 229910052725 zinc Inorganic materials 0.000 claims description 5
- 239000011701 zinc Substances 0.000 claims description 5
- GOGLNICGTBSWDJ-UHFFFAOYSA-N 1,3-thiazepine-7-carboxylic acid Chemical compound OC(=O)C1=CC=CN=CS1 GOGLNICGTBSWDJ-UHFFFAOYSA-N 0.000 claims description 4
- QQVDYSUDFZZPSU-UHFFFAOYSA-M chloromethylidene(dimethyl)azanium;chloride Chemical compound [Cl-].C[N+](C)=CCl QQVDYSUDFZZPSU-UHFFFAOYSA-M 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 125000005544 phthalimido group Chemical group 0.000 claims description 4
- CSRZQMIRAZTJOY-UHFFFAOYSA-N trimethylsilyl iodide Chemical compound C[Si](C)(C)I CSRZQMIRAZTJOY-UHFFFAOYSA-N 0.000 claims description 4
- VHJLVAABSRFDPM-ZXZARUISSA-N dithioerythritol Chemical compound SC[C@H](O)[C@H](O)CS VHJLVAABSRFDPM-ZXZARUISSA-N 0.000 claims description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
- 229910000073 phosphorus hydride Inorganic materials 0.000 claims description 3
- 150000003840 hydrochlorides Chemical class 0.000 claims description 2
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 claims description 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 7
- 150000007513 acids Chemical class 0.000 claims 3
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 claims 1
- OJMIONKXNSYLSR-UHFFFAOYSA-N phosphorous acid Chemical compound OP(O)O OJMIONKXNSYLSR-UHFFFAOYSA-N 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 96
- 239000000243 solution Substances 0.000 description 78
- 239000000047 product Substances 0.000 description 58
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 45
- 239000002002 slurry Substances 0.000 description 33
- 239000011541 reaction mixture Substances 0.000 description 29
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 28
- 238000004128 high performance liquid chromatography Methods 0.000 description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 21
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 20
- 239000000203 mixture Substances 0.000 description 20
- 238000006243 chemical reaction Methods 0.000 description 19
- DKPFZGUDAPQIHT-UHFFFAOYSA-N butyl acetate Chemical compound CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 17
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 229910052757 nitrogen Inorganic materials 0.000 description 14
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- 239000000706 filtrate Substances 0.000 description 11
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 10
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 10
- 239000000543 intermediate Substances 0.000 description 10
- 239000010410 layer Substances 0.000 description 10
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 9
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 9
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- 238000002844 melting Methods 0.000 description 8
- 230000008018 melting Effects 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- 239000003921 oil Substances 0.000 description 7
- 235000019198 oils Nutrition 0.000 description 7
- 239000012074 organic phase Substances 0.000 description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 239000012071 phase Substances 0.000 description 6
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 5
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 5
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 5
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 5
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 5
- 239000013078 crystal Substances 0.000 description 5
- 239000012044 organic layer Substances 0.000 description 5
- BDAWXSQJJCIFIK-UHFFFAOYSA-N potassium methoxide Chemical compound [K+].[O-]C BDAWXSQJJCIFIK-UHFFFAOYSA-N 0.000 description 5
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- ADFXKUOMJKEIND-UHFFFAOYSA-N 1,3-dicyclohexylurea Chemical compound C1CCCCC1NC(=O)NC1CCCCC1 ADFXKUOMJKEIND-UHFFFAOYSA-N 0.000 description 4
- VHJLVAABSRFDPM-UHFFFAOYSA-N 1,4-dithiothreitol Chemical compound SCC(O)C(O)CS VHJLVAABSRFDPM-UHFFFAOYSA-N 0.000 description 4
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 4
- 235000013400 Quercus lobata Nutrition 0.000 description 4
- 240000001749 Quercus lobata Species 0.000 description 4
- 150000008064 anhydrides Chemical class 0.000 description 4
- 239000012267 brine Substances 0.000 description 4
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 238000002425 crystallisation Methods 0.000 description 4
- 230000008025 crystallization Effects 0.000 description 4
- BDUPRNVPXOHWIL-UHFFFAOYSA-N dimethyl sulfite Chemical compound COS(=O)OC BDUPRNVPXOHWIL-UHFFFAOYSA-N 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 235000011181 potassium carbonates Nutrition 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- RQULWPSGQYZREI-LURJTMIESA-N L-Allysine Ethylene Acetal Chemical compound OC(=O)[C@@H](N)CCCC1OCCO1 RQULWPSGQYZREI-LURJTMIESA-N 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 150000001805 chlorine compounds Chemical class 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000004817 gas chromatography Methods 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 229940098779 methanesulfonic acid Drugs 0.000 description 3
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 3
- 235000019796 monopotassium phosphate Nutrition 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 3
- 239000011736 potassium bicarbonate Substances 0.000 description 3
- 235000015497 potassium bicarbonate Nutrition 0.000 description 3
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 3
- 159000000001 potassium salts Chemical class 0.000 description 3
- KEQGZUUPPQEDPF-UHFFFAOYSA-N 1,3-dichloro-5,5-dimethylimidazolidine-2,4-dione Chemical compound CC1(C)N(Cl)C(=O)N(Cl)C1=O KEQGZUUPPQEDPF-UHFFFAOYSA-N 0.000 description 2
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 2
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 102000003729 Neprilysin Human genes 0.000 description 2
- 108090000028 Neprilysin Proteins 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 2
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- XTHPWXDJESJLNJ-UHFFFAOYSA-N chlorosulfonic acid Substances OS(Cl)(=O)=O XTHPWXDJESJLNJ-UHFFFAOYSA-N 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000012456 homogeneous solution Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000012047 saturated solution Substances 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- ISIJQEHRDSCQIU-UHFFFAOYSA-N tert-butyl 2,7-diazaspiro[4.5]decane-7-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCCC11CNCC1 ISIJQEHRDSCQIU-UHFFFAOYSA-N 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- XMEPRJBZFCWFKN-UHFFFAOYSA-N 1,3-Butanedithiol Chemical compound CC(S)CCS XMEPRJBZFCWFKN-UHFFFAOYSA-N 0.000 description 1
- DDTNOZYKKUTJEG-UHFFFAOYSA-N 1,3-dioxolane;pentanoic acid Chemical compound C1COCO1.CCCCC(O)=O DDTNOZYKKUTJEG-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- XVRMRUGVKYSRBZ-UHFFFAOYSA-N 2-amino-6,6-dimethoxyhexanoic acid Chemical compound COC(OC)CCCC(N)C(O)=O XVRMRUGVKYSRBZ-UHFFFAOYSA-N 0.000 description 1
- JMTMSDXUXJISAY-UHFFFAOYSA-N 2H-benzotriazol-4-ol Chemical compound OC1=CC=CC2=C1N=NN2 JMTMSDXUXJISAY-UHFFFAOYSA-N 0.000 description 1
- ZJSQZQMVXKZAGW-UHFFFAOYSA-N 2H-benzotriazol-4-ol hydrate Chemical compound O.OC1=CC=CC2=C1N=NN2 ZJSQZQMVXKZAGW-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- AAXFOHCYSPZZPV-ZETCQYMHSA-N C[C@@H](CCCC(OC)OC)N Chemical class C[C@@H](CCCC(OC)OC)N AAXFOHCYSPZZPV-ZETCQYMHSA-N 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical compound SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 description 1
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 1
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- NNJWFWSBENPGEY-UHFFFAOYSA-N [2-(sulfanylmethyl)phenyl]methanethiol Chemical compound SCC1=CC=CC=C1CS NNJWFWSBENPGEY-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 239000011260 aqueous acid Substances 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 238000010936 aqueous wash Methods 0.000 description 1
- RROBIDXNTUAHFW-UHFFFAOYSA-N benzotriazol-1-yloxy-tris(dimethylamino)phosphanium Chemical compound C1=CC=C2N(O[P+](N(C)C)(N(C)C)N(C)C)N=NC2=C1 RROBIDXNTUAHFW-UHFFFAOYSA-N 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 239000012455 biphasic mixture Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 1
- 229920001429 chelating resin Polymers 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 229940075894 denatured ethanol Drugs 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000002024 ethyl acetate extract Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- MXXGPLSALMCATF-FJXQXJEOSA-N methyl (2s)-2-amino-6,6-dimethoxyhexanoate;hydrochloride Chemical compound Cl.COC(OC)CCC[C@H](N)C(=O)OC MXXGPLSALMCATF-FJXQXJEOSA-N 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- LVRLSYPNFFBYCZ-VGWMRTNUSA-N omapatrilat Chemical compound C([C@H](S)C(=O)N[C@H]1CCS[C@H]2CCC[C@H](N2C1=O)C(=O)O)C1=CC=CC=C1 LVRLSYPNFFBYCZ-VGWMRTNUSA-N 0.000 description 1
- 229950000973 omapatrilat Drugs 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000011970 polystyrene sulfonate Substances 0.000 description 1
- 229960002796 polystyrene sulfonate Drugs 0.000 description 1
- NSETWVJZUWGCKE-UHFFFAOYSA-N propylphosphonic acid Chemical compound CCCP(O)(O)=O NSETWVJZUWGCKE-UHFFFAOYSA-N 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 239000012066 reaction slurry Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- BDZBKCUKTQZUTL-UHFFFAOYSA-N triethyl phosphite Chemical compound CCOP(OCC)OCC BDZBKCUKTQZUTL-UHFFFAOYSA-N 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- FTVLMFQEYACZNP-UHFFFAOYSA-N trimethylsilyl trifluoromethanesulfonate Chemical compound C[Si](C)(C)OS(=O)(=O)C(F)(F)F FTVLMFQEYACZNP-UHFFFAOYSA-N 0.000 description 1
- RMZAYIKUYWXQPB-UHFFFAOYSA-N trioctylphosphane Chemical compound CCCCCCCCP(CCCCCCCC)CCCCCCCC RMZAYIKUYWXQPB-UHFFFAOYSA-N 0.000 description 1
- 238000005292 vacuum distillation Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C323/24—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/25—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C319/00—Preparation of thiols, sulfides, hydropolysulfides or polysulfides
- C07C319/22—Preparation of thiols, sulfides, hydropolysulfides or polysulfides of hydropolysulfides or polysulfides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
하기 화학식 I의 N-보호된-L-호모시스테인 디술피드 또는 그의 활성화 형태를 (S)-2-아미노-6,6-디메톡시헥산산, 메틸 에스테르와 반응시켜 하기 화학식 II의 디술피드 중간체를 생성한다.N-protected-L-homocysteine disulfide of formula (I) or an activated form thereof is reacted with (S) -2-amino-6,6-dimethoxyhexanoic acid, methyl ester to give a disulfide intermediate of formula (II) do.
<화학식 I><Formula I>
<화학식 II><Formula II>
<화학식 III><Formula III>
상기 화학식 II의 디술피드 중간체를 디술피드 결합이 절단되도록 반응시키고, 생성된 단량체를 산촉매 고리화 반응시켜 하기 화학식 III의 N-보호된 락탐을 생성한다.The disulfide intermediate of formula (II) is reacted to cleave the disulfide bond, and the resulting monomer is subjected to an acid catalyst cyclization reaction to produce an N-protected lactam of formula (III).
N-보호기를 제거하여 이중 억제제인 [4S-[4α(R*),7α,10aβ]]-옥타히드로-4-[(2-메르캅토-1-옥소-3-페닐프로필)아미노]-5-옥소-7H-피리도[2,1-b][1,3]티아제핀-7-카르복실산 제조시의 중간체로서 유용한, [4S-(4α,7α,10aβ)]-4-아미노-옥타히드로-5-옥소-7H-피리도[2,1-b][1,3]티아제핀-7-카르복실산, 메틸 에스테르 및 그의 염을 생성한다.N-protecting group was removed to double inhibitor [4S- [4α (R *), 7α, 10aβ]]-octahydro-4-[(2-mercapto-1-oxo-3-phenylpropyl) amino] -5 [4S- (4α, 7α, 10aβ)]-4-amino-, useful as an intermediate in the preparation of oxo-7H-pyrido [2,1-b] [1,3] thiazepine-7-carboxylic acid Octahydro-5-oxo-7H-pyrido [2,1-b] [1,3] thiazepine-7-carboxylic acid, methyl ester and salts thereof are produced.
Description
배경기술Background
로블 (Robl)은 미국 특허 제5,508,272호에서 중성 엔도펩티다제 및 안지오텐신 전환 효소 억제 활성이 있는 하기 화학식의 화합물을 개시했다.Robl discloses compounds of the formula below having neutral endopeptidase and angiotensin converting enzyme inhibitory activity in US Pat. No. 5,508,272.
상기 식에서,Where
A는일 수 있고; X는 S일 수 있고; Y는 CH2일 수 있고; m은 1일 수 있으며; n은 2일 수 있다. 이러한 화합물들 중에서, 최근 임상평가를 받고 있는 것은 [4S-[4α(R*),7α,10aβ]]-옥타히드로-4-[(2-메르캅토-1-옥소-3-페닐프로필)아미노]-5-옥소-7H-피리도[2,1-b][1,3]티아제핀-7-카르복실산이다. 이 화합물은 문헌에서 BMS 186,716 및 오마파트릴라트 (omapatrilat)로 보고되었다.A is Can be; X can be S; Y can be CH 2 ; m can be 1; n may be 2. Among these compounds, the recent clinical evaluation is [4S- [4α (R *), 7α, 10aβ]]-octahydro-4-[(2-mercapto-1-oxo-3-phenylpropyl) amino ] -5-oxo-7H-pyrido [2,1-b] [1,3] thiazepine-7-carboxylic acid. This compound has been reported in the literature as BMS 186,716 and omapatrilat.
로블은 BMS 186,716의 화학식의 아미노 락탐 부분, 즉, 중간체가 화학식의 (S)-2-아미노-6,6-디-메톡시헥산산, 메틸 에스테르를 N-보호된 아미노산 (여기서, P1은 아미노 보호기이고, P2는 황 보호기임)과 커플링시켜 화학식의 디펩티드를 생성함으로써 제조될 수 있다고 개시했다. P2보호기를 제거한 다음, 산촉매 고리화시키고, P1보호기를 제거하면 4S-(4α,7α,10aβ)]-옥타히드로-4-아미노-5-옥소-7H-피리도[2,1-b][1,3]티아제핀-7-카르복실산, 메틸 에스테르가 생성된다.Roble has a chemical formula of BMS 186,716 Aminolactam moiety, that is, the intermediate of formula Of (S) -2-amino-6,6-di-methoxyhexanoic acid, methyl ester, with an N-protected amino acid, wherein P 1 is an amino protecting group and P 2 is a sulfur protecting group It is disclosed that it can be prepared by producing a dipeptides of. Removal of the P 2 protecting group followed by acid catalyst cyclization and removal of the P 1 protecting group resulted in 4S- (4α, 7α, 10aβ)]-octahydro-4-amino-5-oxo-7H-pyrido [2,1-b ] [1,3] thiazepine-7-carboxylic acid, methyl ester is produced.
로블은 P1이 벤질옥시카르보닐, t-부톡시카르보닐, 또는 N-원자와 함께 프탈이미도 등과 같은 보호기를 형성하는 기 등과 같은 아미노 보호기라고 개시했다.Roble disclosed that P 1 is an amino protecting group such as benzyloxycarbonyl, t-butoxycarbonyl, or a group which forms a protecting group such as phthalimido with N-atoms.
발명의 요약Summary of the Invention
본 발명은 [4S-(4α,7α,10aβ)]-4-아미노-옥타히드로-5-옥소-7H-피리도[2,1-b][1,3]티아제핀-7-카르복실산, 메틸 에스테르 및 그의 염의 개선된 화학적 합성법 및 이 합성법에 유용한 신규 디술피드 중간체에 관한 것이다.The present invention relates to [4S- (4α, 7α, 10aβ)]-4-amino-octahydro-5-oxo-7H-pyrido [2,1-b] [1,3] thiazepine-7-carboxylic acid , Improved chemical synthesis of methyl esters and salts thereof and novel disulfide intermediates useful in this synthesis.
본 발명의 방법에 따라서, 하기 화학식 I의 N-보호된-L-호모시스테인 디술피드 또는 N-보호된-L-호모시스테인의 활성화 형태를 (S)-2-아미노-6,6-디메톡시헥산산, 메틸 에스테르와 반응시켜 하기 화학식 II의 디술피드 중간체를 생성한다.According to the process of the present invention, the active form of N-protected-L-homocysteine disulfide or N-protected-L-homocysteine of formula (I) is represented by (S) -2-amino-6,6-dimethoxyhexanoic acid. And a methyl ester to produce a disulfide intermediate of formula II.
그 다음, 상기 화학식 II의 디술피드 중간체를 황-황 결합이 절단되도록 반응시키고, 생성된 단량체를 고리화하여 하기 화학식 III의 N-보호된 락탐을 생성한다.The disulfide intermediate of formula (II) is then reacted to cleave the sulfur-sulfur bond and the resulting monomers are cyclized to produce an N-protected lactam of formula (III).
P1보호기를 제거하여 원하는 락탐 [4S-(4α,7α,10aβ)]-4-아미노-옥타히드로-5-옥소-7H-피리도[2,1-b][1,3]티아제핀-7-카르복실산, 메틸 에스테르를 생성한다. 이 락탐을 히드로할라이드 염 등과 같은 염으로 전환시킬 수 있다.Remove the P 1 protecting group to give the desired lactam [4S- (4α, 7α, 10aβ)]-4-amino-octahydro-5-oxo-7H-pyrido [2,1-b] [1,3] thiazepine- Yields 7-carboxylic acid, methyl ester. This lactam can be converted into a salt such as a hydrohalide salt or the like.
본 발명의 다른 특징에 따라서, 상기 화학식 I의 N-보호된 디술피드 및 (S)-2-아미노-6,6-디메톡시헥산산, 메틸 에스테르를 에틸 아세테이트 용액 중에서 반응시키는 경우, 먼저 (S)-2-아미노-6,6-디메톡시헥산산의 에틸 아세테이트 용액에 에틸렌 글리콜을 제거하는 작용제를 처리한다. 이것으로, 단량체가 상기 화학식 III의 락탐으로 고리화될 때의 하류 불순물이 적어지게 된다. 반응 용매로부터의 에틸렌 글리콜 제거에 적당한 작용제는 폴리(아크릴산 코-아크릴아미드), 칼륨 염 및 염화 칼슘 이수화물이다.According to another feature of the invention, when the N-protected disulfide of formula (I) and (S) -2-amino-6,6-dimethoxyhexanoic acid, methyl ester are reacted in ethyl acetate solution, The ethyl acetate solution of) -2-amino-6,6-dimethoxyhexanoic acid is treated with an agent that removes ethylene glycol. This results in less downstream impurities when the monomer is cyclized to the lactam of formula III. Suitable agents for removal of ethylene glycol from the reaction solvent are poly (acrylic acid co-acrylamide), potassium salts and calcium chloride dihydrate.
발명의 상세한 설명Detailed description of the invention
로블이 미국 특허 제5,508,272호에 기재한 바와 같이, [4S-(4α,7α,10aβ)]-4-아미노-옥타히드로-5-옥소-7H-피리도[2,1-b][1,3]티아제핀-7-카르복실산, 메틸 에스테르 및 그의 염, 특히 그의 히드로할라이드 염은 하기 화학식 VI의 [4S-[4α(R*),7α,10aβ]]-옥타히드로-4-[(2-메르캅토-1-옥소-3-페닐프로필)아미노]-5-옥소-7H-피리도[2,1-b][1,3]티아제핀-7-카르복실산 제조시의 중간체로 유용하다.As Roble described in US Pat. No. 5,508,272, [4S- (4α, 7α, 10aβ)]-4-amino-octahydro-5-oxo-7H-pyrido [2,1-b] [1, 3] thiazepine-7-carboxylic acid, methyl ester and salts thereof, especially hydrohalide salts thereof, are selected from [4S- [4α (R *), 7α, 10aβ]]-octahydro-4-[( 2-mercapto-1-oxo-3-phenylpropyl) amino] -5-oxo-7H-pyrido [2,1-b] [1,3] thiazepine-7-carboxylic acid as an intermediate useful.
본 발명의 방법에 따라서, L-호모시스틴을 2개의 질소 모두에 P1기가 도입되도록 반응시켜 화학식 I의 디술피드를 생성한다. 바람직한 P1보호기로는 트리플루오로아세틸 (L-호모시스틴에 에틸 트리플루오로아세테이트를 처리하여 얻을 수 있음), 페닐메톡시카르보닐 (L-호모시스틴에 벤질 클로로포르메이트를 처리하여 얻을 수 있음), 및 포르밀 (L-호모시스틴에 포름산 및 아세트산 무수물을 처리하여 얻을 수 있음) 등이 있다. 다른 N-보호기, 예를 들면, 프탈이미도, t-부톡시카르보닐 등을 당업계에 공지된 방법에 따라 사용할 수도 있다. 가장 바람직한 P1보호기는 트리플루오로아세틸이다.According to the process of the invention, L-homocystine is reacted to introduce a P 1 group into both nitrogens to produce a disulfide of formula (I). Preferred P 1 protecting groups are trifluoroacetyl (obtained by treatment of ethyl trifluoroacetate with L-homocystine), phenylmethoxycarbonyl (benzyl chloroformate treated with L-homocystin). ), And formyl (obtained by treating L-homocystine with formic acid and acetic anhydride). Other N-protecting groups such as phthalimido, t-butoxycarbonyl and the like can also be used according to methods known in the art. Most preferred P 1 protecting group is trifluoroacetyl.
그 다음, 화학식 I의 N-보호된 디술피드를 (S)-2-아미노-6,6-디메톡시헥산산, 메틸 에스테르와 반응시켜 화학식 II의 디술피드 중간체를 생성한다. 상기 반응은 디시클로헥실카르보디이미드, 1-에틸-3-(3-디메틸아미노프로필)카르보디이미드, 벤조트리아졸-1-일옥시트리스(디메틸아미노)포스포늄 헥사플루오로포스페이트,또는 카르보닐디이미다졸 등과 같은 커플링 시약의 존재하에 수행된다. 바람직한 커플링 시약은 디시클로헥실카르보디이미드이다. P1이 트리플루오로아세틸인 경우, 디시클로헥실카르보디이미드와 함께 1-히드록시벤조트리아졸을 사용하는 것이 바람직하다.The N-protected disulfide of formula (I) is then reacted with (S) -2-amino-6,6-dimethoxyhexanoic acid, methyl ester to produce the disulfide intermediate of formula (II). The reaction is dicyclohexylcarbodiimide, 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide, benzotriazol-1-yloxytris (dimethylamino) phosphonium hexafluorophosphate, or carbo It is carried out in the presence of a coupling reagent such as nildiimidazole and the like. Preferred coupling reagent is dicyclohexylcarbodiimide. When P 1 is trifluoroacetyl, it is preferable to use 1-hydroxybenzotriazole together with dicyclohexylcarbodiimide.
화학식 I의 N-보호된 디술피드가 커플링 시약 없이 (S)-아미노-6,6-디메톡시헥산산, 메틸 에스테르와 반응하는 경우에는 하기 화학식 IIa의 염이 형성될 수 있다. 그 다음, 이 염을 커플링 시약으로 처리하면, 화학식 II의 디술피드 중간체가 생성된다.When the N-protected disulfide of formula (I) is reacted with (S) -amino-6,6-dimethoxyhexanoic acid, methyl ester without coupling reagent, a salt of formula (IIa) may be formed. Treatment of this salt with a coupling reagent then yields the disulfide intermediate of formula (II).
화학식 IIa의 염은 화학식 II의 디술피드 중간체로 전환시키기 전에 저온 및 습기가 없는 조건하에 약 30일 이상의 기간 동안 유지될 수 있는 저장 안정성이 있다. 이것으로 생산 가동 계획에 융통성이 생기고, 상이한 제조 시설에서 상이한 단계의 반응을 수행할 수 있게 된다.Salts of formula (IIa) have a storage stability that can be maintained for a period of at least about 30 days under low temperature and moisture free conditions before conversion to disulfide intermediates of formula (II). This gives flexibility in production run planning and allows different stages of reactions to be carried out at different manufacturing facilities.
별법으로, 상기 화학식 I의 N-보호된 디술피드를 (S)-2-아미노-6,6-디메톡시헥산산, 메틸 에스테르와의 반응 전에 활성화 형태로 전환시킬 수 있다. 상기 활성화 형태로는 산 염화물, 혼합 무수물, 대칭 무수물, 활성화된 에스테르 등이 있다. N-보호된 디술피드의 활성화 형태를 사용하는 경우에는 커플링 시약이 필요없게 된다. 활성화 형태의 선택은 화학식 I의 디술피드의 N-보호기에 따라 달라진다. 상기 보호기가 트리플루오로아세틸인 경우, 적당한 활성화 형태는 산 염화물, 및 활성화된 에스테르 등이며, 산 염화물인 것이 바람직하다. 상기 보호기가 페닐메톡시카르보닐인 경우, 적당한 활성화 형태는 활성화된 에스테르이다.Alternatively, the N-protected disulfide of formula (I) may be converted to the activated form prior to reaction with (S) -2-amino-6,6-dimethoxyhexanoic acid, methyl ester. Such activated forms include acid chlorides, mixed anhydrides, symmetric anhydrides, activated esters, and the like. When using an activated form of N-protected disulfide, no coupling reagent is required. The choice of activation form depends on the N-protecting group of the disulfide of formula (I). When the protecting group is trifluoroacetyl, suitable forms of activation are acid chlorides, activated esters and the like, preferably acid chlorides. If the protecting group is phenylmethoxycarbonyl, the suitable form of activation is an activated ester.
로블은 미국 특허 제5,508,272호에 (S)-2-아미노-6,6-디메톡시헥산산, 메틸 에스테르의 제조 방법을 개시했다. 이 출발 물질을 제조하는 다른 방법은 본 출원의 양수인의 동시 계류 중인 출원에 개시되어 있다. 이 동시 계류 중인 출원에 따르면, 하기 화학식 VII의 디옥솔란 펜탄산을 메탄올 중의 티오닐 클로라이드 또는 메탄올 중의 디메틸 술파이트 및 클로로트리메틸실란과 반응시켜 (S)-2-아미노-6,6-디메톡시헥산산, 메틸 에스테르를 생성할 수 있다. .Rove discloses a process for the preparation of (S) -2-amino-6,6-dimethoxyhexanoic acid, methyl ester in US Pat. No. 5,508,272. Another method of making this starting material is disclosed in the co-pending application of the assignee of the present application. According to this co-pending application, dioxolane pentanic acid of formula (VII) is reacted with thionyl chloride in methanol or dimethyl sulfite and chlorotrimethylsilane in methanol to give (S) -2-amino-6,6-dimethoxyhexane Acids, methyl esters can be produced. .
(S)-2-아미노-6,6-디메톡시헥산산, 메틸 에스테르 및 화학식 I의 N-보호된디술피드 또는 그의 활성화 형태를 유기 용매, 바람직하게는 n-부틸 아세테이트 중에서 반응시킬 수 있다. 상기 반응을 에틸 아세테이트 중에서 수행하는 경우에는, 그 후의 하류 불순물 존재량을 최소화하기 위해 화학식 I의 N-보호된 디술피드와 반응시키기 전에 에틸 아세테이트 중의 (S)-아미노-6,6-디메톡시헥산산, 메틸 에스테르 용액에 에틸렌 글리콜을 제거하는 작용제를 처리한다. 이러한 목적에 적당한 작용제로는 폴리(아크릴산 코-아크릴아미드), 칼륨 염 및 염화 칼슘 이수화물 등이 있다.(S) -2-amino-6,6-dimethoxyhexanoic acid, methyl ester and the N-protected disulfide of formula (I) or their activated form can be reacted in an organic solvent, preferably n-butyl acetate. If the reaction is carried out in ethyl acetate, (S) -amino-6,6-dimethoxyhexane in ethyl acetate before reacting with the N-protected disulfide of formula (I) to minimize subsequent downstream impurities present The agent is treated to remove ethylene glycol in acid, methyl ester solution. Suitable agents for this purpose include poly (acrylic acid co-acrylamide), potassium salts and calcium chloride dihydrate.
이상 (biphasic) 용매계에서 (S)-2-아미노-6,6-디메톡시헥산산, 메틸 에스테르를 화학식 I의 디술피드의 산 염화물 활성화 형태와 반응시키는 것이 유리하다. 이러한 조건하에서는, 우선, 하류 불순물을 최소화하기 위해 에틸렌 글리콜을 제거할 필요가 없다. 적당한 이상 용매계는 유기상으로서의 에틸 및 n-부틸 아세테이트의 혼합물, 및 수성상으로서의 물 및 완충제, 예를 들면, 탄산 칼륨 및 중탄산 칼륨의 혼합물 등을 포함한다.In a biphasic solvent system it is advantageous to react (S) -2-amino-6,6-dimethoxyhexanoic acid, methyl ester with the acid chloride activated form of the disulfide of formula (I). Under these conditions, first, there is no need to remove ethylene glycol to minimize downstream impurities. Suitable bisolvent systems include mixtures of ethyl and n-butyl acetate as organic phases, mixtures of water and buffers as aqueous phases such as potassium carbonate and potassium bicarbonate, and the like.
그 다음, 화학식 II의 N-보호된 디술피드 중간체를 디술피드 결합이 절단되도록 반응시킨 다음, 생성된 단량체를 고리화하여 화학식 III의 N-보호된 락탐을 생성한다. 디술피드 결합의 절단 방법으로는 화학식 II의 중간체를 비스메르캅탄, 포스핀 환원제, 아인산 환원제, 또는 아연 금속 분말과 반응시키는 것 등이 있다. 적당한 비스메르캅탄은 하기 화학식의 화합물을 포함한다.The N-protected disulfide intermediate of formula (II) is then reacted to cleave the disulfide bond, and then the resulting monomer is cyclized to produce an N-protected lactam of formula (III). The method for cleaving disulfide bonds includes reacting an intermediate of formula (II) with a bismercaptan, a phosphine reducing agent, a phosphorous acid reducing agent, or a zinc metal powder. Suitable bismercaptans include compounds of the formula
상기 식에서, k는 1 내지 4의 정수이고; 각각의 X2는 수소 및 히드록시, 및 1,2-벤젠디메탄티올, 1,3-부탄디티올 메소-α,α'-디메르캅토아디프산, 이나트륨 염 (disodium salt), 및 두렌-α(1), α(2)-디티올로부터 독립적으로 선택된다. 바람직하게는, 상기 비스메르캅탄을 나트륨 메톡시드 또는 1,8-디아자비시클로[5.4.0]운데크-7-엔 등과 같은 염기의 존재하에 반응시킨다. 바람직한 비스메르캅탄은 디티오트레이톨 및 디티오에리트리톨이다. 적당한 포스핀 환원제로는 트리부틸 포스핀, 트리옥틸 포스핀, 및 트리페닐 포스핀 등이 있다. 적당한 아인산 환원제로는 트리에틸 아인산 등이 있다. 디술피드 결합의 절단에 바람직한 시약은 트리부틸 포스핀이다.Wherein k is an integer from 1 to 4; Each X 2 is hydrogen and hydroxy, and 1,2-benzenedimethanethiol, 1,3-butanedithiol meso-α, α'-dimercaptoadipic acid, disodium salt, and Independently from durene-α (1), α (2) -dithiol. Preferably, the bismercaptan is reacted in the presence of a base such as sodium methoxide or 1,8-diazabicyclo [5.4.0] undec-7-ene and the like. Preferred bismercaptans are dithiothritol and dithioerythritol. Suitable phosphine reducing agents include tributyl phosphine, trioctyl phosphine, triphenyl phosphine and the like. Suitable phosphorous acid reducing agents include triethyl phosphorous acid and the like. A preferred reagent for cleaving disulfide bonds is tributyl phosphine.
그 다음, 생성된 단량체에 바람직하게는 강산, 예를 들면 트리플루오로아세트산, 클로로술폰산, p-톨루엔술폰산, 메탄술폰산, 트리플루오로메탄술폰산, 트리메틸실릴 트리플루오로메탄술포네이트, 트리메틸실릴 메탄술포네이트 또는 암버라이스트 15 (Amberlyst 15) (등록상표) 등과 같이 시판되는 폴리스티렌 술포네이트 중합체 형의 이온 교환 수지 등으로 처리하여 산촉매 고리화 반응시킨다. 이러한 고리화 반응은 염화 메틸렌 등의 비-양성자 용매에서 바람직하게 수행되거나, 메탄올 등의 양성자 용매 또는 클로로포름 중에서 수행되어 화학식 III의 N-보호된 락탐을 생성할 수 있다.The resulting monomer is then preferably a strong acid, for example trifluoroacetic acid, chlorosulfonic acid, p-toluenesulfonic acid, methanesulfonic acid, trifluoromethanesulfonic acid, trimethylsilyl trifluoromethanesulfonate, trimethylsilyl methanesulfo Acid catalyzed cyclization by treatment with a commercially available polystyrene sulfonate polymer type ion exchange resin such as Nate or Amberberst 15 (registered trademark) or the like. This cyclization reaction may be preferably carried out in a non-protonic solvent such as methylene chloride or in a protonic solvent such as methanol or chloroform to produce an N-protected lactam of formula III.
그 다음, 화학식 III의 N-보호된 락탐에 P1보호기를 제거하는 처리를 하여 [4S-(4α,7α,10aβ)]-4-아미노-옥타히드로-5-옥소-7H-피리도[2,1-b][1,3]티아제핀-7-카르복실산, 메틸 에스테르를 생성한다. 예를 들어, P1이 트리플루오로아세틸인 경우, 메탄올 중의 탄산 칼륨 처리를 이용할 수 있다. P1이 페닐메톡시카르보닐인 경우, 요오도트리메틸실란 또는 탄소 상 팔라듐 및 수소 처리를 이용할 수 있다. P1이 포르밀 또는 t-부톡시카르보닐인 경우, 염산 등의 강산 처리를 이용할 수 있다.The N-protected lactam of formula III was then treated to remove the P 1 protecting group [4S- (4α, 7α, 10aβ)]-4-amino-octahydro-5-oxo-7H-pyrido [2 , 1-b] [1,3] thiazepine-7-carboxylic acid, methyl ester. For example, when P 1 is trifluoroacetyl, potassium carbonate treatment in methanol can be used. When P 1 is phenylmethoxycarbonyl, iodotrimethylsilane or palladium on carbon and hydrogenation can be used. When P 1 is formyl or t-butoxycarbonyl, a strong acid treatment such as hydrochloric acid can be used.
그 다음, 락탐 [4S-(4α,7α,10aβ)]-4-아미노옥타-히드로-5-옥소-7H-피리도 [2,1-b][1,3]티아제핀-7-카르복실산, 메틸 에스테르를 하기 화학식 IV의 아실메르캅토알카노일 측쇄와 반응시켜, 하기 화학식 V을 생성한다.Then, lactam [4S- (4α, 7α, 10aβ)]-4-aminoocta-hydro-5-oxo-7H-pyrido [2,1-b] [1,3] thiazepine-7-carboxyl The acid, methyl ester, is reacted with an acylmercaptoalkanoyl side chain of formula IV to produce formula V
상기 식에서, R6은 메틸 또는 페닐이다.Wherein R 6 is methyl or phenyl.
이러한 커플링 반응은 염화 메틸렌 등과 같은 유기 용매 중에서 및 커플링 시약, 예를 들면, 1-에틸-3-(3-디메틸-아미노프로필)카르보디이미드, 디시클로헥실카르보디이미드, 벤조트리아졸-1-일옥시트리스-(디메틸아미노)포스포늄 헥사플루오로포스페이트, 카르보닐디이미다졸, 또는 1-프로판포스폰산, 고리형 무수물의 존재하에 수행될 수 있다. 별법으로, 상기 화학식 IV의 아실메르캅토알칸산을 커플링 전에 산 염화물, 혼합 무수물, 대칭 무수물, 활성화된 에스테르 등과 같은 활성화 형태로 전환시킬 수 있다. 바람직하게는, 상기 락탐을 히드로할라이드 염 등과 같은 염으로 전환시킨 후에 커플링 반응시킨다. 적당한 히드로할라이드 염은 바람직하게는 히드로클로라이드 염이고, 히드로브로마이드 및 히드로요오드 등도 있다. 상기 염은 상기 락탐 용액을 상응하는 산으로 처리하여 제조할 수 있다.This coupling reaction is carried out in organic solvents such as methylene chloride and the like and coupling reagents such as 1-ethyl-3- (3-dimethyl-aminopropyl) carbodiimide, dicyclohexylcarbodiimide, benzotriazole- It can be carried out in the presence of 1-yloxytris- (dimethylamino) phosphonium hexafluorophosphate, carbonyldiimidazole, or 1-propanephosphonic acid, cyclic anhydride. Alternatively, the acylmercaptoalkanoic acid of formula IV may be converted to an activated form such as acid chloride, mixed anhydride, symmetric anhydride, activated ester, etc. before coupling. Preferably, the lactam is converted to a salt such as a hydrohalide salt or the like followed by a coupling reaction. Suitable hydrohalide salts are preferably hydrochloride salts, including hydrobromide and hydroiodine and the like. The salts can be prepared by treating the lactam solution with the corresponding acid.
화학식 V의 화합물에서 상기 아실기 R6-C(O)-를 제거하고 메틸 에스테르기를 카르복실산으로 전환시켜 화학식 VI의 원하는 최종 생성물을 생성한다. 예를 들어, R6가 메틸인 경우, 메탄올성 수산화 나트륨을 처리한 후에 산 수용액을 처리하면 화학식 VI의 원하는 최종 생성물이 생성된다.The acyl group R 6 -C (O)-in the compound of formula V is removed and the methyl ester group is converted to a carboxylic acid to give the desired final product of formula VI. For example, when R 6 is methyl, treatment with methanolic sodium hydroxide followed by treatment with aqueous acid solution gives the desired final product of formula VI.
[4S-[4α(R*),7α,10aβ]]-옥타히드로-4-[(2-메르캅토-1-옥소-3-페닐프로필)아미노]-5-옥소-7H-피리도[2,1-b][1,3]티아제핀-7-카르복실산에는 안지오텐신 전환 효소 및 중성 엔도펩티다제 억제 활성이 있다. 로블의 미국 특허 제5,508,272호에서 주지된 바와 같이, 상기 화합물 및 그의 제약적으로 허용가능한 염은 고혈압 및 울혈성 심부전 등과 같은 심혈관 질환 치료에 유용하다. 상기 화합물은 인간 등의 포유동물 숙주에게 체중 1 kg 당 일일 약 0.1 mg 내지 약 100 mg, 바람직하게는 체중 1 kg 당 일일 약 0.5 mg 내지 약 25 mg 투여될 수 있다. 상기 화합물은 경구 투여되는 것이 바람직하지만, 비경구 경로 및 국소 경로를 이용할 수도 있다. 일일 용량은 한번에 투여될 수도 있고, 하루 동안 2회 내지 4회에 나누어 투여될 수도 있다.[4S- [4α (R *), 7α, 10aβ]]-octahydro-4-[(2-mercapto-1-oxo-3-phenylpropyl) amino] -5-oxo-7H-pyrido [2 The, 1-b] [1,3] thiazepine-7-carboxylic acid has angiotensin converting enzyme and neutral endopeptidase inhibitory activity. As noted in US Pat. No. 5,508,272 to Roble, the compound and its pharmaceutically acceptable salts are useful for treating cardiovascular diseases such as hypertension and congestive heart failure. The compound may be administered to a mammalian host such as a human from about 0.1 mg to about 100 mg per kg body weight per day, preferably from about 0.5 mg to about 25 mg per kg body weight per day. The compound is preferably administered orally, but parenteral and topical routes may also be employed. The daily dose may be administered at one time or may be divided into two to four times during the day.
하기의 실시예는 본 발명을 설명한다.The following examples illustrate the invention.
실시예 1Example 1
[4S-(4α,7α,10aβ)]-4-아미노-옥타히드로-5-옥소-7H-피리도-[2,1-b][1,3]티아제핀-7-카르복실산, 메틸 에스테르, 히드로클로라이드[4S- (4α, 7α, 10aβ)]-4-amino-octahydro-5-oxo-7H-pyrido- [2,1-b] [1,3] thiazepine-7-carboxylic acid, methyl Esters, hydrochloride
a) N-(트리루오로아세틸)-L-호모시스테인, (1 →1')-디술피드a) N- (triruoacetyl) -L-homocysteine, (1 → 1 ′)-disulfide
고체 L-호모시스틴 (40 kg)에 메탄올 중의 칼륨 메톡시드 용액 (32 중량%, 68.8 kg) 및 메탄올 헹굼액 (42 kg)을 첨가했다. 첨가하는 동안, 온도는 20 ±5℃로 유지시켰고, 백색 수용액이 생성되었다. 상기 용액에 에틸 트리플루오로아세테이트 (43.8 kg)를 첨가하고, 반응 온도를 35 - 40℃로 올렸으며, 상기 반응 혼합물에 6 중량% 염산 (432 kg) 및 에틸 아세테이트 (270 kg)를 처리했다. 층들을 분리하고 유기상을 산성 염수 수용액 (168 kg 물, 18 kg 염화 나트륨, 15 kg 진한 염산)으로 세척했다. 층들을 분리하고 상부의 풍부한 유기상을 20 중량% 염수 수용액 (183 kg)으로 세척했다. 층들을 분리하고 풍부한 에틸 아세테이트 추출물을 연마 여과 (polish filter)하고 신선한 증류물의 수분 함량이 KF = 0.5를 나타낼 때까지, 일정 부피 (110 L)로 공비증류했다 (에틸 아세테이트 400 kg이 추가로 요구되었음). 이 풍부한 에틸 아세테이트의 일부분 (6 kg)을 가열된 (65℃ - 70℃), 교반 중인 헵탄에 첨가하고, 생성된 슬러리를 30분 동안 격렬히 교반했다. 풍부한 에틸 아세테이트 용액의 잔량 (149 kg)을 3.5시간에 걸쳐 첨가했다. 65℃ - 70℃에서 1 시간이 지난 다음, 결정 슬러리를 1.5시간에 걸쳐 15℃ - 25℃로 냉각시켰다. 15℃ - 25℃에서 16시간이 지난 다음, 백색 결정을 단리하고, 원심분리 필터상에서 세척했다 (192 kg 헵탄, 12 kg 에틸 아세테이트). 40℃에서 감압하에 트레이를 건조시켜 표제 화합물을 백색 분말로 36.3 kg 수득했다 (융점: 123.5℃).To solid L-homocystine (40 kg) was added a solution of potassium methoxide (32% by weight, 68.8 kg) in methanol and methanol rinse (42 kg). During the addition, the temperature was maintained at 20 ± 5 ° C. and a white aqueous solution was produced. Ethyl trifluoroacetate (43.8 kg) was added to the solution and the reaction temperature was raised to 35-40 ° C. and the reaction mixture was treated with 6 wt% hydrochloric acid (432 kg) and ethyl acetate (270 kg). The layers were separated and the organic phase was washed with an aqueous acidic brine solution (168 kg water, 18 kg sodium chloride, 15 kg concentrated hydrochloric acid). The layers were separated and the upper rich organic phase was washed with 20 wt% aqueous saline solution (183 kg). The layers were separated and the rich ethyl acetate extract was polish filtered and azeotropically distilled to constant volume (110 L) until the water content of the fresh distillate showed KF = 0.5 (400 kg of ethyl acetate was additionally required. ). A portion (6 kg) of this rich ethyl acetate was added to heated (65 ° C.-70 ° C.), stirring heptane, and the resulting slurry was vigorously stirred for 30 minutes. The remaining amount of rich ethyl acetate solution (149 kg) was added over 3.5 hours. After 1 hour at 65 ° C.-70 ° C., the crystal slurry was cooled to 15 ° C.-25 ° C. over 1.5 hours. After 16 hours at 15 ° C.-25 ° C., white crystals were isolated and washed on a centrifugal filter (192 kg heptane, 12 kg ethyl acetate). The tray was dried at 40 ° C. under reduced pressure to give 36.3 kg of the title compound as a white powder (melting point: 123.5 ° C.).
b) (S)-2-아미노-6,6-디메톡시헥산산, 메틸 에스테르b) (S) -2-amino-6,6-dimethoxyhexanoic acid, methyl ester
질소하에, 메탄올 (240 ml) 중의 (S)-α-아미노-1,3-디옥솔란-2-펜탄산 (20.9 g) 및 디메틸 술파이트 (12.0 g) 슬러리에 클로로트리메틸실란 (28.0 g)을 첨가하여 균질한 용액을 수득했다. 29℃로의 발열을 관찰한 다음, 40 - 45℃로 가열하고, 이 온도에서 8 시간 동안 교반하고, 약 22℃에서 72시간 이하 동안 교반했다. 공정 중간의 (in process) HPLC 분석은 상기 반응이 완결된 것으로 (약 93 M%가 생성물로 전환되었음) 나타났고, 생성된 용액을 -5 ℃ 내지 -10 ℃로 냉각했다. 교반하면서, 32% (또는 4.45 M) 메탄올성 칼륨 메톡시드 용액 (70 ml)을 서서히 주의깊게 첨가하여 혼합물의 겉보기 pH를 pH 11.7 내지 11.9로 조정했고, 이때, 온도는 -5 내지 0 ℃ 범위로 유지시켰다. 생성물 슬러리 분석 (1H NMR)은 중화가 완결된 것으로 나타났다. 먼저, 상기 점성이 낮은 (thin) 슬러리를 30℃ 미만의 진공하에서 300 ml 부피로 농축시킨 다음, 공정 중간의 GC 분석으로 메탄올이 완전히제거되었다고 판단될 때까지 (1 AP 미만), 에틸 아세테이트를 첨가하여 생성물 슬러리의 용매를 에틸 아세테이트로 교환했다. 용매 교환을 완결한 직후, 에틸 아세테이트를 사용하여 배치 (batch) 부피를 약 400 ml로 조정하고, 생성된 슬러리를 여과했다. 상기 여액에 폴리(아크릴산 코-아크릴아미드), 칼륨 염 (3.0 내지 3.2 g) 및 물 (30 - 32 ml)을 첨가했다. 상기 혼합물을 약 35분 동안 교반하고 여과했다. 경우에 따라, 공정 중간의 GC 분석으로 판단했을 때 에틸렌 글리콜의 양이 0.15당량을 넘지 않는다면, 상기 여액에 폴리(아크릴산 코-아크릴아미드), 칼륨 염을 반복 처리할 수 있다. 공정 중간의 HPLC 분석 후, 표제 생성물 17.4 g을 에틸 아세테이트 용액으로 80.8 M% 수율로 수득했다.Under nitrogen, chlorotrimethylsilane (28.0 g) was added to a slurry of (S) -α-amino-1,3-dioxolane-2-pentanoic acid (20.9 g) and dimethyl sulfite (12.0 g) in methanol (240 ml). The addition gave a homogeneous solution. An exotherm to 29 ° C. was observed, then heated to 40-45 ° C., stirred at this temperature for 8 hours, and stirred at about 22 ° C. for up to 72 hours. In process HPLC analysis showed that the reaction was complete (about 93 M% converted to product) and the resulting solution was cooled to -5 ° C to -10 ° C. While stirring, 32% (or 4.45 M) methanolic potassium methoxide solution (70 ml) was added slowly and carefully to adjust the apparent pH of the mixture to pH 11.7 to 11.9, with the temperature in the range -5 to 0 ° C. Maintained. Product slurry analysis ( 1 H NMR) showed that neutralization was complete. First, the thin slurry was concentrated to a volume of 300 ml under vacuum below 30 ° C., and then ethyl acetate was added until GC analysis in the middle of the process determined that methanol was completely removed (below 1 AP). The solvent of the product slurry was exchanged with ethyl acetate. Immediately after completion of the solvent exchange, the batch volume was adjusted to about 400 ml with ethyl acetate and the resulting slurry was filtered. To the filtrate was added poly (acrylic acid co-acrylamide), potassium salt (3.0 to 3.2 g) and water (30-32 ml). The mixture was stirred for about 35 minutes and filtered. In some cases, poly (acrylic acid co-acrylamide) and potassium salts may be repeatedly treated in the filtrate if the amount of ethylene glycol does not exceed 0.15 equivalent, as determined by GC analysis in the middle of the process. After HPLC analysis in the middle of the process, 17.4 g of the title product was obtained in ethyl acetate solution in 80.8 M% yield.
c) 6,6-디메톡시-N-[N-(트리플루오로아세틸)-L-호모시스테이닐]-L-노르루이신, 메틸 에스테르, (1 →1')디술피드c) 6,6-dimethoxy-N- [N- (trifluoroacetyl) -L-homocysteinyl] -L-norleucine, methyl ester, (1 → 1 ′) disulfide
(S)-2-아미노-6,6-디메톡시헥산산, 메틸 에스테르의 에틸 아세테이트 용액 (17.4 g, 용액 328 g, 3.5 w% 물)을 교반하면서, 여기에 N-(트리플루오로아세틸)-L-호모시스테인, (1 →1')-디술피드 (19.5 g), 히드록시벤조트리아졸 (0.7 g, 20w/w% 물) 및 무수 황산 나트륨 (15 g)을 첨가했다. 상기 슬러리를 -2 내지 2 ℃로 냉각시키고, 디시클로헥실카르보디이미드 (19 g)를 이 혼합물의 일부분에 첨가했다 (다소 발열성). 질소 분위기하에서 5 시간 동안 교반한 후의 공정 중간의 HPLC 분석은 상기 반응이 완결된 것으로 나타났다. 농후한 디시클로헥실우레아 및 황산 나트륨 슬러리를 여과하고, 상기 디시클로헥실우레아 습윤-케이크 (wet-cake ) 를 에틸 아세테이트로 세척했다 (2 ×10 ml). 여액을 합해 10% 중탄산 나트륨 용액 (50 ml) 및 염수 포화 용액 (50 ml)으로 세척했다. 온도를 35 - 40 ℃로 유지하면서, 풍부한 에틸 아세테이트 층을 진공하에 부피 130 ml 및 물 함량 0.1 w/w%미만으로 농축했다.While stirring (S) -2-amino-6,6-dimethoxyhexanoic acid, an ethyl acetate solution of methyl ester (17.4 g, 328 g solution, 3.5 w% water), thereto was added N- (trifluoroacetyl) -L-homocysteine, (1 → 1 ′)-disulfide (19.5 g), hydroxybenzotriazole (0.7 g, 20 w / w% water) and anhydrous sodium sulfate (15 g) were added. The slurry was cooled to -2 to 2 ° C and dicyclohexylcarbodiimide (19 g) was added to a portion of this mixture (somewhat exothermic). HPLC analysis in the middle of the process after stirring for 5 hours under nitrogen atmosphere showed that the reaction was complete. It washed the cake (wet-cake) with ethyl acetate (2 × 10 ml) - rich dicyclohexyl urea, and sodium sulfate, filtered and the slurry, and the dicyclohexyl urea wet. The combined filtrates were washed with 10% sodium bicarbonate solution (50 ml) and brine saturated solution (50 ml). While maintaining the temperature at 35-40 ° C., the rich ethyl acetate layer was concentrated under vacuum to a volume of 130 ml and a water content of less than 0.1 w / w%.
상기 풍부한 에틸 아세테이트 용액에 tert-부틸 메틸 에테르 (120 ml)를 첨가하고, 생성된 불투명한 용액을 연마 여과했다. 상기 장치를 1 : 1 에틸 아세테이트/tert-부틸 메틸 에테르로 세척하고 (2 ×10 ml), 세척액을 상기 풍부한 여액과 합했다. 상온에서, 상기 용액에 시클로헥산 (185 ml)을 첨가하고, 결정핵 (seed crystals)을 첨가했다. 생성된 슬러리를 30 분 이상 진탕한 다음, 35분 이상에 걸쳐 시클로헥산 (555 ml)을 추가로 첨가했다. 상기 슬러리를 1 시간 이상 진탕했고, 생성물 습윤-케이크를 6 : 1 : 1 시클로헥산/tert-부틸 메틸 에테르/에틸 아세테이트 용액 (75 ml)으로 세척했다. 상기 습윤-케이크를 약 30 ℃의 진공하에서 건조시켜 표제 생성물 29.8 g을 백색 결정성 고체로 수득했다 (융점: 111-112 ℃).To the rich ethyl acetate solution was added tert-butyl methyl ether (120 ml) and the resulting opaque solution was filtered filtered. The apparatus was washed with 1: 1 ethyl acetate / tert-butyl methyl ether (2 × 10 ml) and the wash was combined with the rich filtrate. At room temperature, cyclohexane (185 ml) was added to the solution and seed crystals were added. The resulting slurry was shaken for at least 30 minutes and then further cyclohexane (555 ml) was added over 35 minutes. The slurry was shaken for at least 1 hour and the product wet-cake was washed with 6: 1: 1 cyclohexane / tert-butyl methyl ether / ethyl acetate solution (75 ml). The wet-cake was dried under vacuum at about 30 ° C. to give 29.8 g of the title product as a white crystalline solid (melting point: 111-112 ° C.).
d) [4S-(4α,7α,10aβ)]-4-아미노-옥타히드로-5-옥소-7H-피리도[2,1-b][1,3]티아제핀-7-카르복실산, 메틸 에스테르, 히드로클로라이드d) [4S- (4α, 7α, 10aβ)]-4-amino-octahydro-5-oxo-7H-pyrido [2,1-b] [1,3] thiazepine-7-carboxylic acid, Methyl ester, hydrochloride
기계적 교반기, 열전대, 질소 주입구 및 환류 응축기가 장착된 1 L 5-구 플라스크에 상기 (c) 부분의 생성물 (41.75 g), 염화 메틸렌 (375 ml) 및 물 (2.7 ml)을 첨가했다. 질소하에, 상기 반응 플라스크를 18-26 ℃에서 진탕시키면서, 여기에 트리부틸 포스핀 (13.24 ml)을 첨가했다. 공정 중간의 HPLC 분석으로 반응이 완결되었다고 판단될 때까지 (1 내지 4 시간), 상기 반응 혼합물을 18 - 26 ℃에서 교반했다. 메르캅탄 용액에 메탄술폰산 (6.8 ml)을 첨가하고, 반응 혼합물을 교반하면서 6 내지 7 시간 동안 환류하에 가열하고, 공정 중간의 HPLC 분석으로 반응이 완결되었다고 판단될 때까지, 12 내지 16 시간 동안 상온에서 교반했다. 반응 혼합물의 용매를 증류를 통해 메탄올과 교환하고, 생성된 [4S-(4α,7α,10aβ)]-옥타히드로-5-옥소-4-[(트리플루오로아세틸)아미노]-7H-피리도[2,1-b][1,3]티아제핀-7-카르복실산, 메틸 에스테르의 메탄올 용액을 40 내지 45 ℃에서 pH를 pH 10.4 내지 10.8로 유지하면서 완충된 (pH 10.5) 1M 탄산 칼륨 용액 (208 ml)으로 처리했다.공정 중간의 HPLC 분석으로 탈보호가 완결되었다고 판단될 때까지, 반응 혼합물을 40 내지 45 ℃에서 교반했다. 36 ℃ 미만에서, 진한 HCl (33.5 ml)을 첨가하여 반응 혼합물의 pH를 pH 5.8 내지 6.5로 조정했다. 급냉된 탈보호 반응 혼합물의 부피가 300 ml이 될 때까지, 37 ℃ 미만의 진공하에서 메탄올을 제거했다. 상기 수용액에 염화 메틸렌을 첨가하고, 진한 HCl (7 ml)을 첨가하여 상기 이상 혼합물의 pH를 pH 0.6 내지 0.9로 조정했다. 상을 분리하고, 생성물 풍부한 수성 층을 추가의 염화 메틸렌 (60 ml)으로 세척했다. 염화 메틸렌 추출물을 합하여 다시 3% HCl 용액 (60 ml)으로 세척하고, 수성 추출물을 상기 생성물 풍부한 수성 층과 합했다. 상기 생성물-풍부 수성 층에 염화 메틸렌 (80 ml)을 첨가하고, 상기 이상 혼합물에 10N 수산화 나트륨 용액 (19 ml)을 첨가하여 pH를 pH 9.0으로 조정한 다음, 1N 수산화 나트륨 용액 (3 ml)을 첨가하여 pH 10.4로 조정했다. 상을 분리하고, 수성 층을 염화 메틸렌 (2 ×80 ml)으로 추출했다. 상기 생성물 풍부한 염화 메틸렌 층을 합하고, 메탄올 (15 ml) 및 클로로트리메틸실란을 첨가했다. 34 내지 37 ℃에서, 표제 화합물의 염화 메틸렌 용액에 에틸 아세테이트 (50 ml)를 서서히 첨가하고 (15 분), 결정화가 뚜렷해질 때까지, 상기 혼합물을 교반했다. 에틸 아세테이트 (175 ml)를 추가로 첨가하여 결정화를 완결했다. 생성된 생성물 슬러리를 15 내지 25 ℃로 냉각하고, 상기 슬러리를 1 시간 이상 교반하고, 생성물을 필터 상에 수집했다. 습윤-케이크를 에틸 아세테이트 (2 ×50 ml)로 세척하고, 생성물을 45 ℃의 진공하에서 (150 mmHg) 16 시간 동안 건조시켜 표제 생성물 25.2 g을 백색 결정성 분말로서 수득했다 (융점: 239 ℃ (분해 온도)).To a 1 L five-necked flask equipped with a mechanical stirrer, thermocouple, nitrogen inlet and reflux condenser was added the product of part (c) (41.75 g), methylene chloride (375 ml) and water (2.7 ml). Under nitrogen, tributyl phosphine (13.24 ml) was added thereto while shaking the reaction flask at 18-26 ° C. The reaction mixture was stirred at 18-26 ° C. until HPLC analysis in the middle of the process determined the reaction was complete (1-4 hours). Methanesulfonic acid (6.8 ml) is added to the mercaptan solution, the reaction mixture is heated under reflux for 6-7 hours with stirring, and at room temperature for 12-16 hours until it is determined that the reaction is complete by HPLC analysis in the middle of the process. Stirred at. The solvent of the reaction mixture was exchanged with methanol via distillation and the resulting [4S- (4α, 7α, 10aβ)]-octahydro-5-oxo-4-[(trifluoroacetyl) amino] -7H-pyrido A methanol solution of [2,1-b] [1,3] thiazepine-7-carboxylic acid, methyl ester, buffered (pH 10.5) 1M potassium carbonate while maintaining the pH at pH 10.4 to 10.8 at 40 to 45 ° C Solution (208 ml). The reaction mixture was stirred at 40-45 ° C. until HPLC analysis in the middle of the process determined that deprotection was complete. Below 36 ° C., concentrated HCl (33.5 ml) was added to adjust the pH of the reaction mixture to pH 5.8-6.5. Methanol was removed under vacuum below 37 ° C. until the volume of the quenched deprotection reaction mixture became 300 ml. Methylene chloride was added to the aqueous solution, and concentrated HCl (7 ml) was added to adjust the pH of the abnormal mixture to pH 0.6 to 0.9. The phases were separated and the product rich aqueous layer was washed with additional methylene chloride (60 ml). The methylene chloride extracts were combined and washed again with 3% HCl solution (60 ml) and the aqueous extracts were combined with the product rich aqueous layer. Methylene chloride (80 ml) is added to the product-rich aqueous layer, 10N sodium hydroxide solution (19 ml) is added to the above mixture to adjust the pH to pH 9.0, and then 1N sodium hydroxide solution (3 ml) is added. Addition was adjusted to pH 10.4. The phases were separated and the aqueous layer was extracted with methylene chloride (2 x 80 ml). The product rich methylene chloride layers were combined and methanol (15 ml) and chlorotrimethylsilane were added. At 34-37 ° C., ethyl acetate (50 ml) was slowly added (15 minutes) to the methylene chloride solution of the title compound and the mixture was stirred until crystallization became apparent. Further ethyl acetate (175 ml) was added to complete the crystallization. The resulting product slurry was cooled to 15-25 ° C, the slurry was stirred for at least 1 hour and the product collected on a filter. The wet-cake was washed with ethyl acetate (2 × 50 ml) and the product was dried under vacuum at 45 ° C. (150 mmHg) for 16 hours to give 25.2 g of the title product as white crystalline powder (melting point: 239 ° C. ( Decomposition temperature)).
실시예 2Example 2
6,6-디메톡시-N-[N-(트리루오로아세틸)-L-호모시스테이닐]-L-노르루이신, 메틸 에스테르 (1 →1')디술피드6,6-dimethoxy-N- [N- (trifluoroacetyl) -L-homocysteinyl] -L-norleucine, methyl ester (1 → 1 ′) disulfide
실시예 1(c)의 생성물은 다음의 방법에 따라 제조될 수도 있다:The product of Example 1 (c) may be prepared according to the following method:
a) (S)-2-아미노-6,6-디메톡시헥산산, 메틸 에스테르a) (S) -2-amino-6,6-dimethoxyhexanoic acid, methyl ester
질소하에, 메탄올 (4560 ml) 중의 (S)-α-아미노-1,3-디옥솔란-2-펜탄산 (380 g) 및 디메틸 술파이트 (228 g)의 슬러리에 클로로트리메틸 실란 (532 g)을 첨가하여 균질한 용액을 수득했다. 29 ℃로의 발열을 관찰한 다음, 상기 용액을 42 ℃로 가열하고, 이 온도에서 8 시간 동안 교반하고, 약 22 ℃에서 16 시간 동안 교반했다. 공정 중간의 HPLC 분석은 생성물이 93 M% 수율로 수득되었음을 나타냈다. 표제 생성물 53.4 g을 함유하는, 생성된 용액의 일부분을 교반하면서 -5 내지 -10 ℃로 냉각시켰고, 32% 메탄올성 칼륨 메톡시드 용액 (2 ×100 ml)을 서서히 주의깊게 첨가하여 혼합물의 겉보기 pH를 pH -0.38 내지 약 8.32로 조정했다. 온도를 -5℃ 미만으로 유지하면서, 칼륨 메톡시드 (16 ml)를 주의깊게 첨가하여 혼합물의 pH를 pH 11.45로 다시 조정했다. 생성물 슬러리의 공정 중간의1H NMR 분석은 중화가 완결된 것으로 나타났다. 30 ℃ 미만에서의 진공 증류를 통해, 생성물 슬러리의 용매를 에틸 아세테이트 (총 3160 ml)로 교환하고, 400 ml 부피로 농축하고, tert-부틸 메틸 에테르 (800 ml)로 희석하고, 0 ℃로 냉각하고, 30분 동안 진탕하여 여과했다. 공정 중간의 GC 분석으로 에틸렌 글리콜이 상기 염화 칼슘 이수화물에 의해 제거된 것으로 나타날 때까지, 상기 여액에 염화 칼슘 이수화물 (9개 부분에 135 g)을 처리했다. 생성된 슬러리를 여과하여 표제 생성물 49.7 g을 함유하는 여액을 수득했다.Chlorotrimethyl silane (532 g) in a slurry of (S) -α-amino-1,3-dioxolane-2-pentanoic acid (380 g) and dimethyl sulfite (228 g) in methanol (4560 ml) under nitrogen Was added to obtain a homogeneous solution. After exotherm to 29 ° C. was observed, the solution was heated to 42 ° C., stirred at this temperature for 8 hours, and stirred at about 22 ° C. for 16 hours. HPLC analysis in the middle of the process showed that the product was obtained in 93 M% yield. A portion of the resulting solution, containing 53.4 g of the title product, was cooled to -5 to -10 ° C with stirring, and the apparent pH of the mixture was added slowly and carefully with 32% methanolic potassium methoxide solution (2 x 100 ml). Was adjusted to pH -0.38 to about 8.32. While maintaining the temperature below −5 ° C., the potassium methoxide (16 ml) was carefully added to adjust the pH of the mixture back to pH 11.45. 1 H NMR analysis in the middle of the process of the product slurry showed that neutralization was complete. Through vacuum distillation below 30 ° C., the solvent of the product slurry is exchanged with ethyl acetate (3160 ml total), concentrated to 400 ml volume, diluted with tert-butyl methyl ether (800 ml) and cooled to 0 ° C. And shaken for 30 minutes and filtered. The filtrate was treated with calcium chloride dihydrate (135 g in 9 portions) until GC analysis in the middle of the process indicated that ethylene glycol was removed by the calcium chloride dihydrate. The resulting slurry was filtered to give a filtrate containing 49.7 g of the title product.
b) 6,6-디메톡시-L-노르루이신, 메틸 에스테르 [S-(R*,R*)]-4,4-디티오비스 [2-[(트리플루오로아세틸)-아미노]부타노에이트 (2 : 1)b) 6,6-dimethoxy-L-norleucine, methyl ester [S- (R *, R *)] -4,4-dithiobis [2-[(trifluoroacetyl) -amino] butano Eight (2: 1)
N-(트리플루오로아세틸)-L-호모시스테인, (1 →1')디술피드 (55.8 g)를 에틸 아세테이트 (200 ml) 중에 용해하고, 생성된 용액을 10분에 걸쳐 (S)-2-아미노-6,6-디메톡시-헥산산, 메틸 에스테르의 tert-부틸 메틸 에테르/에틸 아세테이트 용액 (약 49.7 g, 용액 1787 ml)에 첨가했다. 생성된 혼합물을 1 시간 동안 교반하고, 생성물 슬러리를 여과했다. 습윤-케이크를 tert-부틸 메틸 에테르/에틸 아세테이트 (2 : 1, 250 ml)로 세척하고, 30 ℃의 진공하에서 건조시켜 표제 생성물 98.0 g을 수득했다 (융점: 129.1-129.7 ℃).N- (trifluoroacetyl) -L-homocysteine, (1 → 1 ′) disulfide (55.8 g) is dissolved in ethyl acetate (200 ml) and the resulting solution is (S) -2- over 10 minutes. To amino-6,6-dimethoxy-hexanoic acid, tert-butyl methyl ether / ethyl acetate solution of methyl ester (about 49.7 g, solution 1787 ml). The resulting mixture was stirred for 1 hour and the product slurry was filtered. The wet-cake was washed with tert-butyl methyl ether / ethyl acetate (2: 1, 250 ml) and dried under vacuum at 30 ° C. to give 98.0 g of the title product (melting point: 129.1-129.7 ° C.).
c) 6,6-디메톡시-N-[N-(트리루오로아세틸)-L-호모시스테이닐]-L-노르루이신, 메틸 에스테르, (1 →1')디술피드c) 6,6-dimethoxy-N- [N- (trifluoroacetyl) -L-homocysteinyl] -L-norleucine, methyl ester, (1 → 1 ′) disulfide
상기 (b) 부분에서의 생성물 (95 g), 에틸 아세테이트 (750 ml) 및 물 (13.5 ml)을 상단의 교반기, 질소 주입구, 열전대, 및 온도 제어기가 장착된 3 L 둥근 바닥 플라스크에 충전했다. 상기 반응 혼합물에 히드록시벤조트리아졸 수화물 (1.5 g), 황산 나트륨 (34.5 g) 및 물 (3.5 ml)을 첨가했다. 생성된 용액을 -6 ℃로 냉각하고, 상기 반응 혼합물에 디시클로헥실카르보디이미드 (49.1 g)를 첨가했다. 공정 중간의 HPLC 분석으로 반응이 완결되었다고 판단될 때까지 (5.6 시간), 상기 반응 혼합물을 -2 내지 2 ℃에서 진탕시켰다. 반응 슬러리를 여과하고, 습윤-케이크를 에틸 아세테이트 (2 ×50 ml)로 헹궜다. 여액을 합하여 (925 ml) 중탄산 나트륨 포화 용액 (125 ml) 및 염수 포화 용액 (125 ml)으로 세척했다. 생성된 표제화합물의 에틸 아세테이트 용액을 오일로 농축했다. 상기 오일을 에틸 아세테이트 (900 ml) 중에 용해하고, 오일로 농축하고, 이 오일을 다시 에틸 아세테이트 (300 ml) 중에 용해했다. tert-부틸 메틸 에테르 (300 ml)를 첨가하고, 생성된 용액을 연마 여과하고, 필터-케이크를 1 : 1 에틸 아세테이트/tert-부틸 메틸 에테르 (2 ×25 ml)로 세척했다. 여액을 합하여 시클로헥산 (400 ml) 및 결정핵을 첨가하고, 이 혼합물을 약 30 분 동안 교반했다. 생성된 점성이 낮은 슬러리에, 시클로헥산 (1800 ml)을 75 분에 걸쳐 첨가했다. 16 시간 동안 교반한 다음, 페이퍼를 통해 슬러리를 여과하고 습윤-케이크를 에틸 아세테이트/tert-부틸 메틸 에테르/시클로헥산 (1 : 1 : 6, 175 ml) 용액으로 세척했다. 상기 습윤-케이크 (194 g)를 20 ℃의 진공하에서 건조시켜 백색 표제 생성물 77.6 g을 수득했다 (융점: 111 - 112 ℃).The product (95 g), ethyl acetate (750 ml) and water (13.5 ml) in part (b) were charged to a 3 L round bottom flask equipped with a top stirrer, nitrogen inlet, thermocouple, and temperature controller. To the reaction mixture was added hydroxybenzotriazole hydrate (1.5 g), sodium sulfate (34.5 g) and water (3.5 ml). The resulting solution was cooled to -6 ° C and dicyclohexylcarbodiimide (49.1 g) was added to the reaction mixture. The reaction mixture was shaken at -2 to 2 ° C until HPLC analysis in the middle of the process determined the reaction was complete (5.6 hours). The reaction slurry was filtered and the wet-cake was rinsed with ethyl acetate (2 x 50 ml). The filtrates were combined (925 ml) and washed with saturated sodium bicarbonate solution (125 ml) and brine saturated solution (125 ml). The ethyl acetate solution of the resulting title compound was concentrated to oil. The oil was dissolved in ethyl acetate (900 ml) and concentrated to an oil, which was again dissolved in ethyl acetate (300 ml). tert-butyl methyl ether (300 ml) was added, the resulting solution was filtered filtered and the filter-cake was washed with 1: 1 ethyl acetate / tert-butyl methyl ether (2 × 25 ml). The filtrates were combined and cyclohexane (400 ml) and nuclei were added and the mixture was stirred for about 30 minutes. To the resulting low viscosity slurry, cyclohexane (1800 ml) was added over 75 minutes. After stirring for 16 hours, the slurry was filtered through paper and the wet-cake was washed with a solution of ethyl acetate / tert-butyl methyl ether / cyclohexane (1: 1: 6, 175 ml). The wet-cake (194 g) was dried under vacuum at 20 ° C. to give 77.6 g of white title product (melting point: 111-112 ° C.).
실시예 3Example 3
[4S-(4α,7α,10aβ)]-옥타히드로-5-옥소-4-[[(페닐메톡시)카르보닐]아미노]-7H-피리도-[2,1-b][1,3]티아제핀-7-카르복실산, 메틸 에스테르[4S- (4α, 7α, 10aβ)]-octahydro-5-oxo-4-[[(phenylmethoxy) carbonyl] amino] -7H-pyrido- [2,1-b] [1,3 ] Thiazepine-7-carboxylic acid, methyl ester
a) N-[(페닐메톡시)카르보닐]-L-호모시스테인, (1 →1')-디술피드a) N-[(phenylmethoxy) carbonyl] -L-homocysteine, (1 → 1 ′)-disulfide
1N 수산화 나트륨 용액 (137 ml)을 첨가하여 L-호모시스틴 (15.0 g)을 물 (90 ml) 중에 용해하고, 생성된 pH 13.3 용액을 5 ℃로 냉각시켰다. 1N 수산화 나트륨 용액 (192 ml)을 첨가하여 상기 반응 혼합물의 pH를 약 pH 13으로 유지하면서, 벤질 클로로포르메이트 (21 ml)을 서서히 첨가 (135 분에 걸쳐 첨가)했다. 일단, HPLC 분석으로 반응이 완결되었다고 판단되었을 때, 메틸 이소부틸 케톤 (300 ml 및 400 ml)을 사용하여 추출했다. 염수 포화 용액 (60 ml)을 첨가하여 두번째 추출 동안에 형성된 에멀젼을 파괴하고, 상을 분리시켰다. 풍부한 수용액에 메탄올 (50 ml)을 첨가하고, 진한 염산 용액 (24 ml)을 첨가하여 pH를 약 pH 2로 조정했다. 생성된 생성물 슬러리를 여과하고, 물 (100 ml) 및 1 : 5 메탄올/물 (vol/vol)로 세척하고, 진공하에 18 시간 동안 건조시켜 표제 생성물 28.6 g을 결정성 고체로서 수득했다 (융점: 110 - 115 ℃).1N sodium hydroxide solution (137 ml) was added to dissolve L-homocystin (15.0 g) in water (90 ml) and the resulting pH 13.3 solution was cooled to 5 ° C. Benzyl chloroformate (21 ml) was added slowly (addition over 135 minutes) while 1N sodium hydroxide solution (192 ml) was added to maintain the pH of the reaction mixture at about pH 13. Once determined by HPLC analysis the reaction was complete, extraction was done using methyl isobutyl ketone (300 ml and 400 ml). Saturated brine solution (60 ml) was added to break up the emulsion formed during the second extraction and to separate the phases. To the rich aqueous solution methanol (50 ml) was added and the concentrated hydrochloric acid solution (24 ml) was added to adjust the pH to about pH 2. The resulting product slurry was filtered, washed with water (100 ml) and 1: 5 methanol / water (vol / vol) and dried under vacuum for 18 hours to give 28.6 g of the title product as crystalline solid (melting point: 110-115 ° C).
b) 6,6-디메톡시-N-[N-[(페닐메톡시)카르보닐]-L-호모시스테이닐]-L-노르루이신, 메틸 에스테르, (1 →1')-디술피드b) 6,6-dimethoxy-N- [N-[(phenylmethoxy) carbonyl] -L-homocysteinyl] -L-norleucine, methyl ester, (1 → 1 ′)-disulfide
-4 ℃로 냉각된 (S)-2-아미노-6,6-디메톡시헥산산, 메틸 에스테르 (2.4 g)의 테트라히드로푸란 (45 ml) 용액에 상기 (a) 부분에서의 생성물 (3.0 g)을 첨가했다. 생성된 용액의 일부분에 디시클로헥실카르보디이미드 (2.53 g)를 첨가하고, HPLC 분석으로 완결되었다고 판단될 때까지, 반응 혼합물을 질소 분위기하에서 18 시간 동안 기계적으로 교반했다. 침전된 디시클로헥실우레아를 여과하여 제거하고, 습윤-케이크를 테트라히드로푸란 (15 ml)으로 세척했다. 여액을 합하여 에틸 아세테이트 (150 ml)로 희석하고, pH 3.4의 인산 완충액 (40 ml) 및 중탄산 나트륨 포화 용액 (2 ×60 ml)으로 세척했다. 진공하에 유기층을 오일로 농축하고, 에틸 아세테이트 (45 ml) 중에 재용해시켜 충분량의 헥산으로 희석하여 생성물을 결정화했다. 상온에서, 슬러리를 1 시간 동안 교반한 다음, 생성물 습윤-케이크를 필터 상에 수집하고, 에틸 아세테이트/헵탄 (1 : 2.5) (80 ml)으로 세척했다. 습윤-케이크를 진공하에 건조시켜 표제 생성물 4.22 g을 백색 결정으로 수득했다 (융점: 109 - 110 ℃).The product in part (a) above in a tetrahydrofuran (45 ml) solution of (S) -2-amino-6,6-dimethoxyhexanoic acid, methyl ester (2.4 g) cooled to -4 ° C (3.0 g) ) Was added. Dicyclohexylcarbodiimide (2.53 g) was added to a portion of the resulting solution and the reaction mixture was mechanically stirred under nitrogen atmosphere for 18 hours until judged complete by HPLC analysis. Precipitated dicyclohexylurea was removed by filtration and the wet-cake was washed with tetrahydrofuran (15 ml). The combined filtrates were diluted with ethyl acetate (150 ml) and washed with pH 3.4 phosphate buffer (40 ml) and saturated sodium bicarbonate solution (2 x 60 ml). The organic layer was concentrated to an oil under vacuum, redissolved in ethyl acetate (45 ml) and diluted with sufficient amount of hexane to crystallize the product. At room temperature, the slurry was stirred for 1 hour and then the product wet-cake was collected on a filter and washed with ethyl acetate / heptane (1: 2.5) (80 ml). The wet-cake was dried under vacuum to give 4.22 g of the title product as white crystals (melting point: 109-110 ° C).
c) [4S-(4α,7α,10aβ)]-옥타히드로-5-옥소-4-[[(페닐메톡시)카르보닐]아미노]-7H-피리도-[2,1-b][1,3]티아제핀-7-카르복실산, 메틸 에스테르c) [4S- (4α, 7α, 10aβ)]-octahydro-5-oxo-4-[[(phenylmethoxy) carbonyl] amino] -7H-pyrido- [2,1-b] [1 , 3] thiazepine-7-carboxylic acid, methyl ester
-7 ℃로 냉각된 상기 (b) 부분에서의 생성물 (0.295 g)의 질소 살포된 메틸 아세테이트 용액에 D,L-디티오에리트리톨 (0.06 g)을 첨가했다. 나트륨 메톡시드 용액 (메탄올 중 25%, 0.02 ml)을 상기 반응 혼합물에 첨가하고, HPLC 분석으로 완결되었다고 판단될 때까지, 약 30 분 동안 교반했다. 단량체 용액을 -7 ℃에서 60 분 동안 더 교반하고, 클로로술폰산 (0.018 ml)을 첨가했다. -7 ℃에서 4 시간 동안 계속 교반한 다음, 반응 혼합물을 16 시간 동안 냉동 저장했다. 반응 혼합물을 3% 염산 용액 (2 ×10 ml) 및 중탄산 나트륨 포화 용액 (2 ×8 ml)으로 세척했다. 유기 층을 건조시키고 잔사를 농축하여 표제 생성물 0.31 g을 오일로서 수득했다 (94.2 M%).D, L-dithioerythritol (0.06 g) was added to a nitrogen sparged methyl acetate solution of the product (0.295 g) in part (b) above cooled to -7 ° C. Sodium methoxide solution (25% in methanol, 0.02 ml) was added to the reaction mixture and stirred for about 30 minutes until judged complete by HPLC analysis. The monomer solution was further stirred at −7 ° C. for 60 minutes and chlorosulfonic acid (0.018 ml) was added. Stirring was continued at −7 ° C. for 4 hours, and then the reaction mixture was stored frozen for 16 hours. The reaction mixture was washed with 3% hydrochloric acid solution (2 x 10 ml) and saturated sodium bicarbonate solution (2 x 8 ml). The organic layer was dried and the residue was concentrated to give 0.31 g of the title product as an oil (94.2 M%).
HPLC: Tr = 6.02 분 (UV 210 nm): YMC 염기성 5 마이크론 입자 크기, 4.6 ×250 mm, 40 v/v% (0.01 M 인산 이수소 칼륨 용액, pH 4.0): 60 v/v% 아세토니트릴, 20 ㎕ 주입 부피, 1.0 ml/분으로 유출. 이동상 50 ml 중에 11.8 mg 용해.HPLC: Tr = 6.02 min (UV 210 nm): YMC basic 5 micron particle size, 4.6 x 250 mm, 40 v / v% (0.01 M potassium dihydrogen phosphate solution, pH 4.0): 60 v / v% acetonitrile, 20 μl injection volume, spilled at 1.0 ml / min. Dissolve 11.8 mg in 50 ml of mobile phase.
실시예 4Example 4
[4S-(4α,7α,10aβ)]-4-아미노-옥타히드로-5-옥소-7H-피리도-[2,1-b][1,3]티아제핀-7-카르복실산, 메틸 에스테르, 히드로클로라이드[4S- (4α, 7α, 10aβ)]-4-amino-octahydro-5-oxo-7H-pyrido- [2,1-b] [1,3] thiazepine-7-carboxylic acid, methyl Esters, hydrochloride
a) N-포르밀-L-호모시스테인, (1 →1')-디술피드a) N-formyl-L-homocysteine, (1 → 1 ′)-disulfide
L-호모시스틴 (5.37 g)을 포름산 (23 ml) 중에 용해시켜 점성 용액을 수득하고, 이를 빙욕조에서 5 ℃로 냉각했다. 이 용액에 아세트산 무수물 (11.2 ml)을 약 4 분에 걸쳐 적가하고, 반응 혼합물의 온도를 약 10 ℃로 올렸다. HPLC 분석으로 완결되었다고 판단될 때까지, 이 반응 혼합물을 6 시간 동안 교반했다. 빙수 (10 ml)를 첨가하여 반응 혼합물을 급냉시킨 다음, 회전 증발기 상에서 백색 잔사로 농축했다. 백색 잔사를 상온의 진공하에서 더욱 건조시켰다. 생성된 건조한 백색 분말 (6.9 g)을 환류 중인 클로로포름 (40 ml) 중에 현탁하고, 변성된 에탄올 (SDA 35A, 8 ml)을 첨가했다. 이 혼합물을 약 20 ℃로 냉각시키고, 생성물을 여과하고 습윤-케이크를 냉각 클로로포름으로 세척했다. 진공하에 건조시킨 다음, 표제 생성물을 백색 결정성 분말로 단리했다 (5.85 g, 90 M%).L-homocystine (5.37 g) was dissolved in formic acid (23 ml) to give a viscous solution, which was cooled to 5 ° C. in an ice bath. Acetic anhydride (11.2 ml) was added dropwise to this solution over about 4 minutes, and the temperature of the reaction mixture was raised to about 10 ° C. The reaction mixture was stirred for 6 hours until judged complete by HPLC analysis. Iced water (10 ml) was added to quench the reaction mixture and then concentrated to a white residue on a rotary evaporator. The white residue was further dried under vacuum at room temperature. The resulting dry white powder (6.9 g) was suspended in refluxing chloroform (40 ml) and denatured ethanol (SDA 35A, 8 ml) was added. The mixture was cooled to about 20 ° C, the product was filtered and the wet-cake was washed with cold chloroform. After drying in vacuo, the title product was isolated as a white crystalline powder (5.85 g, 90 M%).
b) N-(N-포르밀-L-호모시스테이닐)-6,6-디메톡시-L-노르루이신, 메틸 에스테르, (1 →1')-디술피드b) N- (N-formyl-L-homocysteinyl) -6,6-dimethoxy-L-norleucine, methyl ester, (1 → 1 ′)-disulfide
22 ℃에서, 상기 (a) 부분에서의 생성물 (1.62 g)의 테트라히드로푸란 (45 ml) 슬러리에 (S)-2-아미노-6,6-디메톡시헥산산, 메틸 에스테르 (2.05 g)를 첨가했다. 생성된 두껍고, 끈적끈적한 슬러리를 약 10분 동안 진탕하고, 디시클로헥실카르보디이미드 (2.29 g)를 첨가했다. 진탕한 지 약 15분 후에는 반응이 진행됨에 따라, 끈적끈적한 슬러리가 미분 백색 분말로 바뀌었다. TLC 분석으로 완결되었다고 판단될 때까지, 반응물을 15 시간 동안 진탕했다. 침전된 디시클로헥실우레아를 여과하여 제거하고, 습윤-케이크를 테트라히드로푸란 (10 ml)으로 세척했다. 여액을 합하여 회전 증발기 상에서 농축하고, 잔사를 염화 메틸렌 (100 ml) 중에 용해했다. 생성된 용액을 물 (50 ml), 5% 시트르산 (50 ml) 및 5% 중탄산 나트륨 용액 (50 ml)으로 세척했다. 유기 층을 황산 마그네슘 상에서 건조시키고, 회전 증발기 상에서 건조될 때까지 농축시켜 생성물 (3.82 g)을 끈적끈적한 포움 (foam)으로 수득했다. 포움을 에틸 아세테이트 중의 5 부피% 메탄올 내지 에틸 아세테이트 중의 10 부피% 메탄올의 용매 구배를 사용한 방사 크로마토그래피로 정제하여 생성물 2.83 g (81 M%)을 황색 유리로서 수득했다. 생성된 황색 유리를 환류 중인 에틸 아세테이트 중에 용해하고, 헥산 (30 ml)을 흐림점에 첨가했다. 생성된 혼합물을 상온에서 16 시간 동안 교반하고, 생성물을 여과하고 습윤-케이크를 헥산 (2 ×4 ml)으로 세척했다. 진공하에 생성물을 건조시켜 생성물 1.3 g (37.2 M%)을 비결정성 고체로 수득했다 (융점: 88-92 ℃).To 22 ° C., (S) -2-amino-6,6-dimethoxyhexanoic acid, methyl ester (2.05 g) was added to a slurry of tetrahydrofuran (45 ml) of the product (1.62 g) in part (a) above. Added. The resulting thick, sticky slurry was shaken for about 10 minutes and dicyclohexylcarbodiimide (2.29 g) was added. After about 15 minutes of shaking, as the reaction proceeded, the sticky slurry turned to a fine white powder. The reaction was shaken for 15 hours until judged complete by TLC analysis. Precipitated dicyclohexylurea was removed by filtration and the wet-cake was washed with tetrahydrofuran (10 ml). The filtrates were combined and concentrated on a rotary evaporator and the residue dissolved in methylene chloride (100 ml). The resulting solution was washed with water (50 ml), 5% citric acid (50 ml) and 5% sodium bicarbonate solution (50 ml). The organic layer was dried over magnesium sulfate and concentrated to dryness on a rotary evaporator to give the product (3.82 g) as a sticky foam. The foam was purified by spinning chromatography using a solvent gradient of 5 vol% methanol in ethyl acetate to 10 vol% methanol in ethyl acetate to give 2.83 g (81 M%) of the product as a yellow glass. The resulting yellow glass was dissolved in reflux ethyl acetate and hexane (30 ml) was added to the cloud point. The resulting mixture was stirred at ambient temperature for 16 hours, the product was filtered and the wet-cake was washed with hexane (2 x 4 ml). The product was dried under vacuum to give 1.3 g (37.2 M%) of the product as an amorphous solid (melting point: 88-92 ° C).
c) [4S-(4α,7α,10aβ)]-옥타히드로-5-옥소-4-(N-포르밀)-7H-피리도[2,1-b][1,3]티아제핀-7-카르복실산, 메틸 에스테르c) [4S- (4α, 7α, 10aβ)]-octahydro-5-oxo-4- (N-formyl) -7H-pyrido [2,1-b] [1,3] thiazepine-7 -Carboxylic acid, methyl ester
-10 ℃로 냉각된 상기 (b) 부분에서의 생성물 (1.05 g)의 질소 살포된 메틸 아세테이트 용액에 D,L-디티오에리트리톨 (0.24 g)을 첨가했다. 상기 반응 혼합물에 나트륨 메톡시드 용액 (메탄올 중 25%, 0.07 ml)을 첨가하고, 약 16 시간 동안 교반했다. 상기 반응 혼합물을 HPLC 분석한 다음, D,L-디티오에리트리톨 (0.03 g) 및 나트륨 메톡시드 용액 (메탄올 중 25%, 0.01 ml)을 추가로 첨가하고, 반응 혼합물을 1 시간 동안 교반했다. 상기 반응 혼합물을 HPLC 분석한 다음, D,L-디티오에리트리톨 (0.06 g) 및 나트륨 메톡시드 용액 (메탄올 중 25%, 0.01 ml)을 추가로첨가하고, HPLC 분석으로 완결되었다고 판단될 때까지, 반응 혼합물을 교반했다. 단량체 용액을 0.01 M 황산 (10 ml) 및 중탄산 나트륨 포화 용액 (10 ml)으로 세척했다. 유기 층을 회전 증발기 상에서 농축하여 조 단량체를 농후한 액체로서 수득했다 (0.84 g, 80M%). 상기 단량체를 메틸 아세테이트 중에 용해하고, 생성된 용액을 질소를 사용하여 살포한 후, 암버라이스트 15 (등록상표) (2 g)를 첨가했다. HPLC 분석으로 반응이 완결되었다고 판단될 때까지 (16 시간), 상기 반응 혼합물을 10 내지 15 ℃에서 교반했다. 수지를 여과해내고, 메틸 아세테이트 (15 ml)로 세척했다. 여액을 중탄산 나트륨 포화 용액 (2 ×10 ml)으로 세척하고, 수성 세척액을 다시 메틸 아세테이트 (2 ×5 ml)로 추출했다. 유기 층들을 합하여 진공하에 농축하여 표제 생성물 0.6 g (87 M%)을 잔사로 수득했다.D, L-dithioerythritol (0.24 g) was added to a nitrogen sparged methyl acetate solution of the product (1.05 g) in part (b) above cooled to -10 ° C. To the reaction mixture was added sodium methoxide solution (25% in methanol, 0.07 ml) and stirred for about 16 hours. The reaction mixture was analyzed by HPLC, then additional D, L-dithioerythritol (0.03 g) and sodium methoxide solution (25% in methanol, 0.01 ml) were added and the reaction mixture was stirred for 1 hour. The reaction mixture was analyzed by HPLC, then additionally added D, L-dithioerythritol (0.06 g) and sodium methoxide solution (25% in methanol, 0.01 ml), until judged complete by HPLC analysis. The reaction mixture was stirred. The monomer solution was washed with 0.01 M sulfuric acid (10 ml) and saturated sodium bicarbonate solution (10 ml). The organic layer was concentrated on a rotary evaporator to give the crude monomer as a thick liquid (0.84 g, 80 M%). The monomer was dissolved in methyl acetate and the resulting solution was sparged with nitrogen, followed by the addition of Amberlite 15® (2 g). The reaction mixture was stirred at 10-15 ° C. until HPLC analysis determined the reaction was complete (16 hours). The resin was filtered off and washed with methyl acetate (15 ml). The filtrate was washed with saturated sodium bicarbonate solution (2 × 10 ml) and the aqueous wash was extracted again with methyl acetate (2 × 5 ml). The combined organic layers were concentrated in vacuo to yield 0.6 g (87 M%) of the title product as a residue.
HPLC: Tr = 8.42 분. (UV 210 nm); YMC 염기성 5 마이크론 입자 크기, 4.6 ×250 mm, 75 v/v% (0.01 M 인산 이수소 칼륨 용액, pH 4.0): 25 v/v% 아세토니트릴, 20 ㎕ 주입 부피, 1.0 ml/분으로 용출.HPLC: Tr = 8.42 min. (UV 210 nm); YMC basic 5 micron particle size, 4.6 × 250 mm, 75 v / v% (0.01 M potassium dihydrogen phosphate solution, pH 4.0): 25 v / v% acetonitrile, 20 μl injection volume, eluted at 1.0 ml / min.
d) [4S-(4α,7α,10aβ)]-4-아미노-옥타히드로-5-옥소-7H-피리도[2,1-b][1,3]티아제핀-7-카르복실산, 메틸 에스테르, 히드로클로라이드d) [4S- (4α, 7α, 10aβ)]-4-amino-octahydro-5-oxo-7H-pyrido [2,1-b] [1,3] thiazepine-7-carboxylic acid, Methyl ester, hydrochloride
상기 (c) 부분에서의 생성물 (0.6 g)의 메탄올 용액 (8 ml)에 진한 염산(0.4 ml)을 첨가하고, 이 용액을 물 (0.4 ml)로 희석했다. HPLC 분석으로 완결되었다고 판단될 때까지 (72 시간), 상기 반응 혼합물을 상온에서 교반했다. 진공하에 메탄올을 제거하고, 잔사를 1N 염산 (10 ml) 중에 용해하고, 염화 메틸렌 (2 ×6 ml)으로 세척했다. 탄산 칼륨을 사용하여 수성 층을 pH 10.5로 염기성화하고, 염화 메틸렌 (6 ×8 ml)을 사용하여 상기 용액을 추출했다. 진공하에 유기 추출물을 농축하여 표제 생성물 0.37 g (49 M%)을 잔사로 수득했다.Concentrated hydrochloric acid (0.4 ml) was added to a methanol solution (8 ml) of the product (0.6 g) in part (c) above, and the solution was diluted with water (0.4 ml). The reaction mixture was stirred at room temperature until judged complete by HPLC analysis (72 hours). Methanol was removed under vacuum, and the residue was dissolved in 1N hydrochloric acid (10 ml) and washed with methylene chloride (2 x 6 ml). The aqueous layer was basified to pH 10.5 with potassium carbonate and the solution was extracted using methylene chloride (6 x 8 ml). The organic extracts were concentrated in vacuo to give 0.37 g (49 M%) of the title product as a residue.
HPLC: Tr = 3.86 분. (UV 210 nm): YMC 염기성 5 마이크론 입자 크기, 4.6 ×250 mm, 75 v/v% (0.01 M 인산 이수소 칼륨 용액, pH 4.0): 25 v/v% 아세토니트릴, 20 ㎕ 주입 부피, 1.0 ml/분으로 용출.HPLC: Tr = 3.86 min. (UV 210 nm): YMC basic 5 micron particle size, 4.6 × 250 mm, 75 v / v% (0.01 M potassium dihydrogen phosphate solution, pH 4.0): 25 v / v% acetonitrile, 20 μl injection volume, 1.0 Elution at ml / min.
실시예 5Example 5
[4S-(4α,7α, 10aβ)]-옥타히드로-5-옥소-4-[(트리플루오로아세틸)아미노]-7H-피리도-[2,1-b][1,3]티아제핀-7-카르복실산, 메틸 에스테르[4S- (4α, 7α, 10aβ)]-octahydro-5-oxo-4-[(trifluoroacetyl) amino] -7H-pyrido- [2,1-b] [1,3] thiazepine -7-carboxylic acid, methyl ester
염화 메틸렌/메탄올 (20 ml, 8 : 2) 중에 실시예 1(c)로부터의 생성물 (2.0g)을 용해시키고, 아연 금속 분말 (0.45 g)을 첨가했다. 이 현탁액에 메탄술폰산 (2.3 g, 10 당량)을 첨가하고, HPLC 분석으로 완결되었다고 판단될 때까지, 상기 혼합물을 실온에서 교반했다. 전형적으로, 상기 반응이 완결되는데에는 약 1 내지 2 시간이 소요된다. 상기 생성물 스트림을 물 (10 ml)로 세척하고, 염화 메틸렌 용액을 건조될 때까지 농축시켜 원하는 생성물을 오일로서 수득했다 (1.1667 g, 68.7 M%).The product (2.0 g) from Example 1 (c) was dissolved in methylene chloride / methanol (20 ml, 8: 2) and zinc metal powder (0.45 g) was added. Methanesulfonic acid (2.3 g, 10 equiv) was added to this suspension and the mixture was stirred at room temperature until judged complete by HPLC analysis. Typically, the reaction takes about 1 to 2 hours to complete. The product stream was washed with water (10 ml) and the methylene chloride solution was concentrated to dryness to give the desired product as an oil (1.1667 g, 68.7 M%).
실시예 1(d)에 기재한 바와 같이, 이 오일은 메탄올 중에 용해시켜 탄산 칼륨 용액과 반응시킨 다음, 진한 염산을 첨가하면 [4S-(4α,7α,10aβ)]-4-아미노-옥타히드로-5-옥소-7H-피리도[2,1-b][1,3]티아제핀-7-카르복실산, 메틸 에스테르, 히드로클로라이드로 전환될 수 있다.As described in Example 1 (d), this oil was dissolved in methanol, reacted with potassium carbonate solution, and then concentrated hydrochloric acid was added to [4S- (4α, 7α, 10aβ)]-4-amino-octahydro. -5-oxo-7H-pyrido [2,1-b] [1,3] thiazepine-7-carboxylic acid, methyl ester, hydrochloride.
실시예 6Example 6
6,6-디메톡시-N-[N-트리플루오로아세틸)-L-호모시스테이닐]-L-노르루이신, 메틸 에스테르, (1 →1')-디술피드6,6-dimethoxy-N- [N-trifluoroacetyl) -L-homocysteinyl] -L-norleucine, methyl ester, (1 → 1 ′)-disulfide
실시예 1(c) 및 실시예 2의 생성물은 다음과 같이 제조될 수도 있다:The products of Example 1 (c) and Example 2 may be prepared as follows:
a) N-(트리플루오로아세틸)-L-호모시스테인, (1 →1')-디술피드a) N- (trifluoroacetyl) -L-homocysteine, (1 → 1 ′)-disulfide
실시예 1(a)의 생성물은 다음과 같이 제조될 수도 있다:The product of Example 1 (a) may be prepared as follows:
질소하에, 메탄올 (22.97 g) 중의 L-호모시스틴 (13.34 g) 및 32% 칼륨 메톡시드를 상단의 교반기, 온도계, 질소 주입구, 통풍구, 및 첨가 깔때기가 장착된 500 ml 3-구 둥근 바닥 플라스크에 충전했다. 첨가 깔때기를 메탄올 (10.2 g)로헹구고, 헹굼액을 상기 혼합물에 첨가했다. 생성된 슬러리를 30 내지 40분 동안 실온에서 빠르게 진탕시키면서 철저히 교반하여 맑은 용액을 수득했다. 생성된 용액에 에틸 트리플루오로아세테이트 (15.2 g)를 반응 온도가 35 내지 40 ℃로 유지되는 비율로 첨가했다. 첨가 깔때기를 메탄올 (2.7 g)로 헹구고, 헹굼액을 상기 반응 혼합물에 첨가했다. 공정 중간의 HPLC 분석으로 완결되었다고 판단될 때까지, 상기 반응 혼합물을 38 내지 40 ℃에서 가열했다. 상기 반응 혼합물에 메탄올 (2.7 g)을 충전하고, 실온 (약 25 ℃)으로 냉각시켰다. 산성화된 염수 수용액 [143.4 g, 진한 염산 (12 g) 및 염화 나트륨 (1.44 g)을 물 (130 g)에 용해시켜 제조] 및 n-부틸 아세테이트 (100 ml)를 상기 혼합물에 첨가했다. 상을 분리하고 유기상을 12% 및 24% 염수 용액 (각 60 g 씩)으로 연속 세척했다. 세척한 유기상이 총 부피 160 ml이 되도록 n-부틸 아세테이트 (60 ml)로 희석한 다음, 증류물의 물 함량이 0.2% 미만이 될 때까지 55 내지 60 ℃에서 농축했다. 약 25 ℃에서 냉각한 후에, 상기 생성물 용액에 헵탄 (80 ml) 및 약간의 결정핵 (30 mg)을 첨가했다. 상기 결정화 혼합물에 60분에 걸쳐 헵탄 (200 ml)을 추가로 서서히 첨가했다. 생성된 슬러리를 약 25 ℃에서 1 내지 4 시간 동안 교반하고, 생성물을 필터 상에 수집했다. 생성물 습윤-케이크를 9 : 1 헵탄/n-부틸 아세테이트 (50 ml)로 세척한 후에 헵탄 (50 ml)으로 세척한 다음, 밤새 (16-18 시간) 진공 건조시켜 (25 torr, 45 ℃.) 표제 생성물 20.7 g을 수득했다.Under nitrogen, L-homocystine (13.34 g) and 32% potassium methoxide in methanol (22.97 g) were placed in a 500 ml 3-necked round bottom flask equipped with a stirrer, thermometer, nitrogen inlet, vent, and addition funnel at the top. Charged. The addition funnel was rinsed with methanol (10.2 g) and rinse solution was added to the mixture. The resulting slurry was thoroughly stirred with rapid shaking at room temperature for 30-40 minutes to obtain a clear solution. To the resulting solution was added ethyl trifluoroacetate (15.2 g) at a rate such that the reaction temperature was maintained at 35-40 ° C. The addition funnel was rinsed with methanol (2.7 g) and the rinse was added to the reaction mixture. The reaction mixture was heated at 38-40 ° C. until judged complete by HPLC analysis in the middle of the process. The reaction mixture was charged with methanol (2.7 g) and cooled to room temperature (about 25 ° C). Acidified saline solution [143.4 g, concentrated hydrochloric acid (12 g) and sodium chloride (1.44 g) dissolved in water (130 g)] and n-butyl acetate (100 ml) were added to the mixture. The phases were separated and the organic phase was washed successively with 12% and 24% brine solutions (60 g each). The washed organic phase was diluted with n-butyl acetate (60 ml) to a total volume of 160 ml and then concentrated at 55-60 ° C. until the water content of the distillate was less than 0.2%. After cooling to about 25 ° C., heptane (80 ml) and some nuclei (30 mg) were added to the product solution. Heptane (200 ml) was further slowly added to the crystallization mixture over 60 minutes. The resulting slurry was stirred at about 25 ° C. for 1-4 hours and the product collected on a filter. The product wet-cake was washed with 9: 1 heptane / n-butyl acetate (50 ml) followed by heptane (50 ml) and then vacuum dried overnight (16-18 hours) (25 torr, 45 ° C.) 20.7 g of the title product were obtained.
HPLC: Tr = 5 분. (UV 210 nm): E. Merck Lichrosorb NH2, 250 ×5 mm, 5 마이크론, 25 v% 0.025 M NH4OAc, pH = 4.5: 75 v% 아세토니트릴, 20 ㎕ 주입 부피, 1.0 ml/분으로 용출.HPLC: Tr = 5 min. (UV 210 nm): E. Merck Lichrosorb NH 2 , 250 × 5 mm, 5 microns, 25 v% 0.025 M NH 4 OAc, pH = 4.5: 75 v% acetonitrile, 20 μl injection volume, 1.0 ml / min Elution.
b) (S)-2-아미노-6,6-디메톡시헥산산, 메틸 에스테르b) (S) -2-amino-6,6-dimethoxyhexanoic acid, methyl ester
실시예 1(b)의 생성물은 다음과 같이 제조될 수도 있다:The product of Example 1 (b) may be prepared as follows:
질소하에, (S)-α-아미노-1,3-디옥솔란-2-펜탄산 (25.0 g), 메탄올 (300 ml) 및 디메틸 술파이트 (12.32 ml)를 기계적 교반기, 열전대, 가열기, 질소 주입구 및 발포기가 장착된 500 ml 3-구 둥근 바닥 플라스크에 첨가했다. 생성된 슬러리에 클로로트리메틸실란 (41.95 ml)을 첨가하고 8 시간 동안 40 ℃에서 가열하여 (S)-2-아미노-6,6-디메톡시헥산산, 메틸 에스테르, 히드로클로라이드 염을 생성했다. 약 25 ℃로 냉각한 다음, 메탄올 (100 ml) 중의 중탄산 칼륨 (52.15 g) 슬러리에 히드로클로라이드 염 용액을 pH가 pH 7 보다 높게 유지되는 비율로 첨가하여 (총 첨가 시간은 약 1 시간) 중화시켰다. n-부틸 아세테이트 (200 ml)를 첨가하고, 슬러리를 온도 30 ℃ 미만으로 유지하면서 진공하에 (110 내지 30 torr) 농축하여 메탄올을 제거했다. 중화된 (S)-2-아미노-6,6-디메톡시헥산산, 메틸 에스테르 슬러리를 0 - 5 ℃에서 유지하면서, 다음 단계를 수행했다.Under nitrogen, (S) -α-amino-1,3-dioxolane-2-pentanoic acid (25.0 g), methanol (300 ml) and dimethyl sulfite (12.32 ml) were added to a mechanical stirrer, thermocouple, heater, nitrogen inlet. And a 500 ml three-neck round bottom flask equipped with a foamer. Chlorotrimethylsilane (41.95 ml) was added to the resulting slurry and heated at 40 ° C. for 8 hours to give (S) -2-amino-6,6-dimethoxyhexanoic acid, methyl ester, hydrochloride salt. After cooling to about 25 ° C., the hydrochloride salt solution was added to a slurry of potassium bicarbonate (52.15 g) in methanol (100 ml) at a rate such that the pH was maintained above pH 7 (total addition time was about 1 hour). . n-butyl acetate (200 ml) was added and the slurry was concentrated under vacuum (110-30 torr) while maintaining the temperature below 30 ° C. to remove methanol. The following steps were performed while maintaining the neutralized (S) -2-amino-6,6-dimethoxyhexanoic acid, methyl ester slurry at 0-5 ° C.
c) N-(트리플루오로아세틸)-L-호모시스테인, (1 →1')디술피드, 이산 클로라이드c) N- (trifluoroacetyl) -L-homocysteine, (1 → 1 ′) disulfide, diacid chloride
질소하에, N-(트리플루오로아세틸)-L-호모시스테인, (1 →1')디술피드 (25.34 g), 에틸 아세테이트 (150 ml) 및 n-부틸 아세테이트 (75 ml)를 기계적 진탕기, 열전대, 가열기, 질소 주입구 및 발포기가 장착된 500 ml 3-구 둥근 바닥 플라스크에 충전했다. 생성된 용액을 -10 ℃로 냉각했다. 생성된 용액에 (클로로메틸렌)디메틸암모늄 클로라이드 (빌스마이어 (Vilsmeier) 시약, 16.9 g)를 충전하고, 공정 중간의 HPLC 분석으로 반응이 완결되었다고 판단될 때까지, -5 내지 -11 ℃에서 교반했다.Under nitrogen, N- (trifluoroacetyl) -L-homocysteine, (1 → 1 ′) disulfide (25.34 g), ethyl acetate (150 ml) and n-butyl acetate (75 ml) were added to a mechanical shaker, thermocouple. A 500 ml three-necked round bottom flask equipped with a heater, a nitrogen inlet and a foamer was charged. The resulting solution was cooled to -10 ° C. The resulting solution was charged with (chloromethylene) dimethylammonium chloride (Vilsmeier reagent, 16.9 g) and stirred at -5 to -11 ° C until the reaction was judged complete by HPLC analysis in the middle of the process. .
d) 6,6-디메톡시-N-[N-(트리플루오로아세틸)-L-호모시스테이닐]-L-노르루이신, 메틸 에스테르 (1 →1')디술피드d) 6,6-dimethoxy-N- [N- (trifluoroacetyl) -L-homocysteinyl] -L-norleucine, methyl ester (1 → 1 ′) disulfide
물 (250 ml) 중 중탄산 칼륨 (22.03 g)의 냉각 용액 (0 - 5 ℃)을 상기 (b) 부분에서의 (S)-2-아미노-6,6-디메톡시헥산산, 메틸 에스테르의 n-부틸 아세테이트 슬러리에 첨가하여 격렬히 진탕시키고, 이 혼합물에 20 w/v% 탄산 칼륨 수용액을 가하여 pH를 pH 8.5로 조정했다. 그 다음, -1 내지 5 ℃에서, 상기 (c) 부분에서의 이산 클로라이드 용액을 (S)-2-아미노-6,6-디메톡시헥산산, 메틸 에스테르의 격렬히 교반된 이상 혼합물에 서서히 (1 내지 2 시간에 걸쳐) 첨가하면서, 20% 탄산 칼륨 수용액으로 이산 클로라이드 첨가 동안의 pH를 pH 8.0 - 8.5로 유지했다. 이산 클로라이드 첨가 깔때기를 냉각 (0 내지 5 ℃) 에틸 아세테이트 (12.5 ml)로 헹구고, 상기 헹굼액을 상기 반응 혼합물에 첨가했다. 이산 클로라이드 첨가가 완료된 지 30분 후에, 상을 분리하고 유기상을 물 (2 ×250 ml)로 세척했다. 60 내지 70 ℃의 진공하에서, 풍부한 유기상을 약 250 ml 부피로 농축한 다음, 땅콩 오일 (14.5 ml) 및 헵탄 (550 ml)을 첨가했다. 결정화 혼합물을 60 내지 70 ℃에서 30분 이하 동안 교반하여 결정이 양호하게 형성되도록 했다. 결정 슬러리에 냉각/가열/냉각 프로토콜을 교대로 적용하고, 20 내지 25 ℃에서 냉각한 다음, 생성물을 필터 상에 수집했다. 생성된 습윤-케이크를 1 : 4 n-부틸 아세테이트/헵탄 (2 ×130 ml) 및 헵탄 (130 ml)으로 세척했다. 45 ℃ 미만의 진공하에서 생성물 습윤-케이크를 건조시켜 원하는 생성물 41 g을 HPLC 영역 비율(%)이 91 - 94인 백색 고체로서 수득했다.A cold solution of potassium bicarbonate (22.03 g) in water (250 ml) (0-5 ° C.) was added to (S) -2-amino-6,6-dimethoxyhexanoic acid, methyl ester in part (b) above. The mixture was added to the butyl acetate slurry and vigorously shaken, and the pH was adjusted to pH 8.5 by adding 20 w / v% aqueous potassium carbonate solution. Then, at −1 to 5 ° C., the diacid chloride solution in part (c) was slowly added to a vigorously stirred biphasic mixture of (S) -2-amino-6,6-dimethoxyhexanoic acid, methyl ester (1 To 2 hours), the pH during the diacid chloride addition was maintained at pH 8.0-8.5 with 20% aqueous potassium carbonate solution. The diacid chloride addition funnel was rinsed with cold (0-5 ° C.) ethyl acetate (12.5 ml) and the rinse was added to the reaction mixture. 30 minutes after completion of the diacid chloride addition, the phases were separated and the organic phase was washed with water (2 × 250 ml). Under vacuum at 60-70 ° C., the rich organic phase was concentrated to about 250 ml volume, then peanut oil (14.5 ml) and heptane (550 ml) were added. The crystallization mixture was stirred at 60-70 ° C. for up to 30 minutes to ensure good crystal formation. Cooling / heating / cooling protocols were alternately applied to the crystalline slurry, cooled at 20-25 ° C., and the product collected on a filter. The resulting wet-cake was washed with 1: 4 n-butyl acetate / heptane (2 × 130 ml) and heptanes (130 ml). The product wet-cake was dried under vacuum below 45 [deg.] C. to give 41 g of the desired product as a white solid with HPLC region percentages of 91-94.
Claims (28)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US1999/015380 WO2002042258A1 (en) | 1998-07-15 | 1999-07-29 | PREPARATION OF [4S-(4α,7α,10Aβ)]-4-AMINO-OCTAHYDRO-5-OXO-7H-PYRIDO[2,1-B][1,3]THIAZEPINE-7-CARBOXYLIC ACID, METHYL ESTER AND SALTS THEREOF VIA NOVEL DISULFIDES |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20020067490A true KR20020067490A (en) | 2002-08-22 |
Family
ID=22273156
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020027001165A KR20020067490A (en) | 1999-07-29 | 1999-07-29 | Preparation of [4S-(4α,7α,10aβ)]-4-Amino-Octahydro-5-Oxo-7H-Pyrido[2,1-b][1,3]Thiazepine-7-Carboxylic Acid, Methyl Ester and Salts Thereof via Novel Disulfides |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1235792A4 (en) |
JP (1) | JP2004514665A (en) |
KR (1) | KR20020067490A (en) |
HK (1) | HK1048802A1 (en) |
HU (1) | HUP0202462A3 (en) |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6340752B1 (en) * | 1998-01-06 | 2002-01-22 | Bristol-Myers Squibb Co. | Deprotection and recrystallization processes |
-
1999
- 1999-07-29 KR KR1020027001165A patent/KR20020067490A/en not_active Application Discontinuation
- 1999-07-29 EP EP99974268A patent/EP1235792A4/en not_active Withdrawn
- 1999-07-29 HU HU0202462A patent/HUP0202462A3/en unknown
- 1999-07-29 JP JP2002544394A patent/JP2004514665A/en active Pending
-
2003
- 2003-02-06 HK HK03100856.0A patent/HK1048802A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
JP2004514665A (en) | 2004-05-20 |
EP1235792A4 (en) | 2003-06-25 |
EP1235792A1 (en) | 2002-09-04 |
HUP0202462A3 (en) | 2005-01-28 |
HUP0202462A2 (en) | 2002-11-28 |
HK1048802A1 (en) | 2003-04-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69130408T2 (en) | Endothelin antagonistic peptide derivatives | |
EP0618926B1 (en) | New peptide derivatives | |
RU2108322C1 (en) | Derivatives of cycloalkyl-substituted glutaric acid amide and pharmaceutical composition based on thereof | |
JP3942670B2 (en) | Benzazepine-N-acetic acid derivatives, benzoxyazepine-N-acetic acid derivatives and benzothiaazepine-N-acetic acid derivatives, methods for producing the derivatives, and pharmaceuticals containing the compounds | |
AU625456B2 (en) | Diol-containing renin inhibitors | |
JP3569550B2 (en) | Fused bicyclic ring-containing compound and method for producing the same | |
IE873383L (en) | Phosphinic acid derivatives | |
EP0172347A2 (en) | Renin inhibiting compounds | |
EP1600457A1 (en) | Peptide derivatives having beta-secretase inhibitory activity | |
SK82198A3 (en) | Prodrugs of thrombin inhibitors | |
AU1602597A (en) | Serine protease inhibitors | |
US6410684B1 (en) | Serine protease inhibitors | |
EP0078228A1 (en) | Novel peptide compounds, a process for manufacturing them, pharmaceutical compositions containing them, and methods for treating ulcer and thrombus with them | |
SK287682B6 (en) | Antithrombotic compound, method for producing thereof, pharmaceutical compositions containing the same and use thereof | |
EP0187037A2 (en) | Piperidine derivatives, their production and use | |
JP4023554B2 (en) | Derivatives of aminosulfonic acid, use of the derivatives in the synthesis of pseudopeptides, and production methods thereof | |
EP0228625B1 (en) | Peptide derivatives inhibitors of hydroxyling enzymes, their process of preparation, the agents thereof and their use | |
AU766558B2 (en) | Preparation of (4S-(4alpha,7alpha,10Abeta))-4-amino-octahydro-5-oxo-7H- pyrido(2,1-B)(1,3)thiazepine-7-carboxylic acid, methyl ester and salts thereof via novel disulfides | |
JP3165698B2 (en) | Thioacylating reagents and intermediates, thiopeptides, and their preparation and use | |
US4490386A (en) | Phosphate salts of 1-[2-[(1-alkoxycarbonyl-3-aralkyl)-amino]-1-oxoalkyl]octahydro-1H-indole-2-carboxylic acids, preparation of, and medical compositions thereof | |
EP0518676A2 (en) | Cyclic renin inhibitors | |
KR20020067490A (en) | Preparation of [4S-(4α,7α,10aβ)]-4-Amino-Octahydro-5-Oxo-7H-Pyrido[2,1-b][1,3]Thiazepine-7-Carboxylic Acid, Methyl Ester and Salts Thereof via Novel Disulfides | |
KR890004365B1 (en) | Process for the preparation of difluorocyclostatine containing polypetides | |
MXPA01004887A (en) | PREPARATION OF [4S-(4agr;,7agr;,10Abgr;)]-4-AMINO-OCTAHYDRO-5-OXO-7H-PYRIDO[2,1-B][1, 3]THIAZEPINE-7-CARBOXYLIC ACID, METHYL ESTER AND SALTS THEREOF VIA NOVEL DISULFIDES | |
US4636560A (en) | Amino thiol peptides |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |